Difference between revisions of "Classical Hodgkin lymphoma - historical"
m (Text replacement - "style="background-color:#1a9851" |Phase III" to "style="background-color:#1a9851" |Phase 3") |
Wayneliang (talk | contribs) (Moved non-current pediatric regimens to this page) Tag: visualeditor-switched |
||
Line 1: | Line 1: | ||
The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. As a general rule, this includes the inferior arm(s) of a randomized study, unless said regimens continue to be recommended by trustworthy sources such as the [http://www.nccn.org/professionals/physician_gls/f_guidelines.asp NCCN Guidelines]. Is there a regimen missing from this list? See the [[Hodgkin_lymphoma|main Hodgkin lymphoma page]] for current regimens. | The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. As a general rule, this includes the inferior arm(s) of a randomized study, unless said regimens continue to be recommended by trustworthy sources such as the [http://www.nccn.org/professionals/physician_gls/f_guidelines.asp NCCN Guidelines]. Is there a regimen missing from this list? See the [[Hodgkin_lymphoma|main Hodgkin lymphoma page]] for current regimens. | ||
− | |||
{| class="wikitable" style="float:right; margin-right: 5px;" | {| class="wikitable" style="float:right; margin-right: 5px;" | ||
|- | |- | ||
|<div style="background-color: #fee0d1; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}" align="right"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Regimen |limit=10000|format=sum}} [[Tutorial#Regimens|regimens]] on this page</b></font></div> | |<div style="background-color: #fee0d1; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}" align="right"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Regimen |limit=10000|format=sum}} [[Tutorial#Regimens|regimens]] on this page</b></font></div> | ||
<div style="background-color: #deebf6; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Variant |limit=10000|format=sum}} [[Tutorial#Variants|variants]] on this page</b></font></div> | <div style="background-color: #deebf6; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Variant |limit=10000|format=sum}} [[Tutorial#Variants|variants]] on this page</b></font></div> | ||
− | |} | + | |} |
− | |||
{{TOC limit|limit=3}} | {{TOC limit|limit=3}} | ||
− | |||
=Untreated= | =Untreated= | ||
− | |||
==ABVDm {{#subobject:3065be|Regimen=1}}== | ==ABVDm {{#subobject:3065be|Regimen=1}}== | ||
{| class="wikitable" style="float:right; margin-left: 5px;" | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
Line 18: | Line 14: | ||
ABVDm: '''<u>A</u>'''driamycin (Doxorubicin), '''<u>B</u>'''leomycin, '''<u>V</u>'''inblastine, '''<u>D</u>'''acarbazine, '''<u>m</u>'''ethylprednisolone | ABVDm: '''<u>A</u>'''driamycin (Doxorubicin), '''<u>B</u>'''leomycin, '''<u>V</u>'''inblastine, '''<u>D</u>'''acarbazine, '''<u>m</u>'''ethylprednisolone | ||
===Regimen {{#subobject:c39ab4|Variant=1}}=== | ===Regimen {{#subobject:c39ab4|Variant=1}}=== | ||
− | {| class="wikitable sortable" style="width: 100%; text-align:center;" | + | {| class="wikitable sortable" style="width: 100%; text-align:center;" |
!style="width: 20%"|Study | !style="width: 20%"|Study | ||
!style="width: 20%"|Years of enrollment | !style="width: 20%"|Years of enrollment | ||
Line 40: | Line 36: | ||
===References=== | ===References=== | ||
# '''H90-NM:''' Le Maignan C, Desablens B, Delwail V, Dib M, Berthou C, Vigier M, Ghandour C, Atmani S, Casassus P, Maisonneuve H, Le Mevel A, Traulle C, Bernard M, Briere J, Colonna P, Andrieu JM. Three cycles of adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD) or epirubicin, bleomycin, vinblastine, and methotrexate (EBVM) plus extended field radiation therapy in early and intermediate Hodgkin disease: 10-year results of a randomized trial. Blood. 2004 Jan 1;103(1):58-66. Epub 2003 Aug 7. [http://www.bloodjournal.org/content/103/1/58.long link to original article] [https://pubmed.ncbi.nlm.nih.gov/12907440 PubMed] | # '''H90-NM:''' Le Maignan C, Desablens B, Delwail V, Dib M, Berthou C, Vigier M, Ghandour C, Atmani S, Casassus P, Maisonneuve H, Le Mevel A, Traulle C, Bernard M, Briere J, Colonna P, Andrieu JM. Three cycles of adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD) or epirubicin, bleomycin, vinblastine, and methotrexate (EBVM) plus extended field radiation therapy in early and intermediate Hodgkin disease: 10-year results of a randomized trial. Blood. 2004 Jan 1;103(1):58-66. Epub 2003 Aug 7. [http://www.bloodjournal.org/content/103/1/58.long link to original article] [https://pubmed.ncbi.nlm.nih.gov/12907440 PubMed] | ||
− | |||
==BCVPP {{#subobject:75779b|Regimen=1}}== | ==BCVPP {{#subobject:75779b|Regimen=1}}== | ||
{| class="wikitable" style="float:right; margin-left: 5px;" | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
Line 48: | Line 43: | ||
BCVPP: '''<u>B</u>'''CNU (Carmustine), '''<u>C</u>'''yclophosphamide, '''<u>V</u>'''incristine, '''<u>P</u>'''rocarbazine, '''<u>P</u>'''rednisone | BCVPP: '''<u>B</u>'''CNU (Carmustine), '''<u>C</u>'''yclophosphamide, '''<u>V</u>'''incristine, '''<u>P</u>'''rocarbazine, '''<u>P</u>'''rednisone | ||
===Regimen {{#subobject:ab3db2|Variant=1}}=== | ===Regimen {{#subobject:ab3db2|Variant=1}}=== | ||
− | {| class="wikitable sortable" style="width: 100%; text-align:center;" | + | {| class="wikitable sortable" style="width: 100%; text-align:center;" |
!style="width: 20%"|Study | !style="width: 20%"|Study | ||
!style="width: 20%"|Years of enrollment | !style="width: 20%"|Years of enrollment | ||
Line 75: | Line 70: | ||
*[[Procarbazine (Matulane)]] | *[[Procarbazine (Matulane)]] | ||
*[[Prednisone (Sterapred)]] | *[[Prednisone (Sterapred)]] | ||
− | |||
===References=== | ===References=== | ||
# Durant JR, Gams RA, Velez-Garcia E, Bartolucci A, Wirtschafter D, Dorfman R. BCNU, velban, cyclophosphamide, procarbazine, and prednisone (BVCPP) in advanced Hodgkin's disease. Cancer. 1978 Nov;42(5):2101-10. [https://onlinelibrary.wiley.com/doi/abs/10.1002/1097-0142%28197811%2942%3A5%3C2101%3A%3AAID-CNCR2820420504%3E3.0.CO%3B2-M link to original article] [https://pubmed.ncbi.nlm.nih.gov/719600 PubMed] | # Durant JR, Gams RA, Velez-Garcia E, Bartolucci A, Wirtschafter D, Dorfman R. BCNU, velban, cyclophosphamide, procarbazine, and prednisone (BVCPP) in advanced Hodgkin's disease. Cancer. 1978 Nov;42(5):2101-10. [https://onlinelibrary.wiley.com/doi/abs/10.1002/1097-0142%28197811%2942%3A5%3C2101%3A%3AAID-CNCR2820420504%3E3.0.CO%3B2-M link to original article] [https://pubmed.ncbi.nlm.nih.gov/719600 PubMed] | ||
# Bakemeier RF, Anderson JR, Costello W, Rosner G, Horton J, Glick JH, Hines JD, Berard CW, DeVita VT Jr; [[Study_Groups#ECOG|ECOG]]. BCVPP chemotherapy for advanced Hodgkin's disease: evidence for greater duration of complete remission, greater survival, and less toxicity than with a MOPP regimen: results of the Eastern Cooperative Oncology Group study. Ann Intern Med. 1984 Oct;101(4):447-56. [http://annals.org/aim/article-abstract/698988/bcvpp-chemotherapy-advanced-hodgkin-s-disease-evidence-greater-duration-complete link to original article] [https://pubmed.ncbi.nlm.nih.gov/6089632 PubMed] | # Bakemeier RF, Anderson JR, Costello W, Rosner G, Horton J, Glick JH, Hines JD, Berard CW, DeVita VT Jr; [[Study_Groups#ECOG|ECOG]]. BCVPP chemotherapy for advanced Hodgkin's disease: evidence for greater duration of complete remission, greater survival, and less toxicity than with a MOPP regimen: results of the Eastern Cooperative Oncology Group study. Ann Intern Med. 1984 Oct;101(4):447-56. [http://annals.org/aim/article-abstract/698988/bcvpp-chemotherapy-advanced-hodgkin-s-disease-evidence-greater-duration-complete link to original article] [https://pubmed.ncbi.nlm.nih.gov/6089632 PubMed] | ||
− | |||
==ChlVPP/PABIOE {{#subobject:8ee324|Regimen=1}}== | ==ChlVPP/PABIOE {{#subobject:8ee324|Regimen=1}}== | ||
{| class="wikitable" style="float:right; margin-left: 5px;" | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
Line 87: | Line 80: | ||
ChlVPP/PABIOE: '''<u>Chl</u>'''orambucil, '''<u>V</u>'''inblastine, '''<u>P</u>'''rocarbazine, '''<u>P</u>'''rednisone alternating with '''<u>P</u>'''rednisolone, '''<u>A</u>'''driamycin (Doxorubicin), '''<u>B</u>'''leomycin, '''<u>O</u>'''ncovin (Vincristine), '''<u>E</u>'''toposide | ChlVPP/PABIOE: '''<u>Chl</u>'''orambucil, '''<u>V</u>'''inblastine, '''<u>P</u>'''rocarbazine, '''<u>P</u>'''rednisone alternating with '''<u>P</u>'''rednisolone, '''<u>A</u>'''driamycin (Doxorubicin), '''<u>B</u>'''leomycin, '''<u>O</u>'''ncovin (Vincristine), '''<u>E</u>'''toposide | ||
===Protocol {{#subobject:48feb0|Variant=1}}=== | ===Protocol {{#subobject:48feb0|Variant=1}}=== | ||
− | {| class="wikitable sortable" style="width: 100%; text-align:center;" | + | {| class="wikitable sortable" style="width: 100%; text-align:center;" |
!style="width: 20%"|Study | !style="width: 20%"|Study | ||
!style="width: 20%"|Years of enrollment | !style="width: 20%"|Years of enrollment | ||
Line 112: | Line 105: | ||
*[[Vincristine (Oncovin)]] | *[[Vincristine (Oncovin)]] | ||
*[[Etoposide (Vepesid)]] | *[[Etoposide (Vepesid)]] | ||
− | |||
===References=== | ===References=== | ||
# Hancock BW, Gregory WM, Cullen MH, Hudson GV, Burton A, Selby P, Maclennan KA, Jack A, Bessell EM, Smith P, Linch DC; British National Lymphoma Investigation; Central Lymphoma Group. ChlVPP alternating with PABlOE is superior to PABlOE alone in the initial treatment of advanced Hodgkin's disease: results of a British National Lymphoma Investigation/Central Lymphoma Group randomized controlled trial. Br J Cancer. 2001 May 18;84(10):1293-300. [https://www.nature.com/articles/6691778 link to orginal article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363648/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/11355937 PubMed] | # Hancock BW, Gregory WM, Cullen MH, Hudson GV, Burton A, Selby P, Maclennan KA, Jack A, Bessell EM, Smith P, Linch DC; British National Lymphoma Investigation; Central Lymphoma Group. ChlVPP alternating with PABlOE is superior to PABlOE alone in the initial treatment of advanced Hodgkin's disease: results of a British National Lymphoma Investigation/Central Lymphoma Group randomized controlled trial. Br J Cancer. 2001 May 18;84(10):1293-300. [https://www.nature.com/articles/6691778 link to orginal article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363648/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/11355937 PubMed] | ||
# '''UKLG LY09:''' Johnson PW, Radford JA, Cullen MH, Sydes MR, Walewski J, Jack AS, MacLennan KA, Stenning SP, Clawson S, Smith P, Ryder D, Hancock BW; United Kingdom Lymphoma Group. Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin's lymphoma: results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519). J Clin Oncol. 2005 Dec 20;23(36):9208-18. Epub 2005 Nov 28. [https://doi.org/10.1200/JCO.2005.03.2151 link to original article] '''contains verified protocol''' [https://pubmed.ncbi.nlm.nih.gov/16314615 PubMed] ISRCTN97144519 | # '''UKLG LY09:''' Johnson PW, Radford JA, Cullen MH, Sydes MR, Walewski J, Jack AS, MacLennan KA, Stenning SP, Clawson S, Smith P, Ryder D, Hancock BW; United Kingdom Lymphoma Group. Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin's lymphoma: results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519). J Clin Oncol. 2005 Dec 20;23(36):9208-18. Epub 2005 Nov 28. [https://doi.org/10.1200/JCO.2005.03.2151 link to original article] '''contains verified protocol''' [https://pubmed.ncbi.nlm.nih.gov/16314615 PubMed] ISRCTN97144519 | ||
## '''Subgroup analysis:''' Johnson PW, Sydes MR, Hancock BW, Cullen M, Radford JA, Stenning SP. Consolidation radiotherapy in patients with advanced Hodgkin's lymphoma: survival data from the UKLG LY09 randomized controlled trial (ISRCTN97144519). J Clin Oncol. 2010 Jul 10;28(20):3352-9. Epub 2010 May 24. [https://doi.org/10.1200/JCO.2009.26.0323 link to original article] [https://pubmed.ncbi.nlm.nih.gov/20498402 PubMed] | ## '''Subgroup analysis:''' Johnson PW, Sydes MR, Hancock BW, Cullen M, Radford JA, Stenning SP. Consolidation radiotherapy in patients with advanced Hodgkin's lymphoma: survival data from the UKLG LY09 randomized controlled trial (ISRCTN97144519). J Clin Oncol. 2010 Jul 10;28(20):3352-9. Epub 2010 May 24. [https://doi.org/10.1200/JCO.2009.26.0323 link to original article] [https://pubmed.ncbi.nlm.nih.gov/20498402 PubMed] | ||
− | |||
==COMP {{#subobject:8ee324|Regimen=1}}== | ==COMP {{#subobject:8ee324|Regimen=1}}== | ||
{| class="wikitable" style="float:right; margin-left: 5px;" | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
Line 125: | Line 116: | ||
COMP: '''<u>C</u>'''yclophosphamide, '''<u>O</u>'''ncovin (Vincristine), '''<u>M</u>'''ethotrexate, '''<u>P</u>'''rednisone | COMP: '''<u>C</u>'''yclophosphamide, '''<u>O</u>'''ncovin (Vincristine), '''<u>M</u>'''ethotrexate, '''<u>P</u>'''rednisone | ||
===Regimen {{#subobject:48feb0|Variant=1}}=== | ===Regimen {{#subobject:48feb0|Variant=1}}=== | ||
− | {| class="wikitable" style="width: 40%; text-align:center;" | + | {| class="wikitable" style="width: 40%; text-align:center;" |
!style="width: 25%"|Study | !style="width: 25%"|Study | ||
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]] | !style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
Line 140: | Line 131: | ||
===References=== | ===References=== | ||
# Moxley JH 3rd, De Vita VT, Brace K, Frei E 3rd. Intensive combination chemotherapy and X-irradiation in Hodgkin's disease. Cancer Res. 1967 Jul;27(7):1258-63. [http://cancerres.aacrjournals.org/content/27/7/1258.long link to original article] [https://pubmed.ncbi.nlm.nih.gov/4952914 PubMed] | # Moxley JH 3rd, De Vita VT, Brace K, Frei E 3rd. Intensive combination chemotherapy and X-irradiation in Hodgkin's disease. Cancer Res. 1967 Jul;27(7):1258-63. [http://cancerres.aacrjournals.org/content/27/7/1258.long link to original article] [https://pubmed.ncbi.nlm.nih.gov/4952914 PubMed] | ||
− | |||
==COPP (CCNU) {{#subobject:86879b|Regimen=1}}== | ==COPP (CCNU) {{#subobject:86879b|Regimen=1}}== | ||
{| class="wikitable" style="float:right; margin-left: 5px;" | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
Line 146: | Line 136: | ||
|[[#top|back to top]] | |[[#top|back to top]] | ||
|} | |} | ||
− | |||
COPP: '''<u>C</u>'''CNU (Lomustine), '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rocarbazine, '''<u>P</u>'''rednisone | COPP: '''<u>C</u>'''CNU (Lomustine), '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rocarbazine, '''<u>P</u>'''rednisone | ||
− | |||
===Regimen {{#subobject:cf3db2|Variant=1}}=== | ===Regimen {{#subobject:cf3db2|Variant=1}}=== | ||
− | {| class="wikitable sortable" style="width: 100%; text-align:center;" | + | {| class="wikitable sortable" style="width: 100%; text-align:center;" |
!style="width: 20%"|Study | !style="width: 20%"|Study | ||
!style="width: 20%"|Years of enrollment | !style="width: 20%"|Years of enrollment | ||
Line 175: | Line 163: | ||
*[[Procarbazine (Matulane)]] | *[[Procarbazine (Matulane)]] | ||
*[[Prednisone (Sterapred)]] | *[[Prednisone (Sterapred)]] | ||
− | |||
===References=== | ===References=== | ||
# Cooper MR, Pajak TF, Nissen NI, Stutzman L, Brunner K, Cuttner J, Falkson G, Grunwald H, Bank A, Leone L, Seligman BR, Silver RT, Weiss RB, Haurani F, Blom J, Spurr CL, Glidewell OJ, Gottlieb AJ, Holland JF. A new effective four-drug combination of CCNU (1-[2-chloroethyl]-3-cyclohexyl-1-nitrosourea) (NSC-79038), vinblastine, prednisone, and procarbazine for the treatment of advanced Hodgkin's disease. Cancer. 1980 Aug 15;46(4):654-62. [https://onlinelibrary.wiley.com/doi/10.1002/1097-0142(19800815)46:4%3C654::AID-CNCR2820460405%3E3.0.CO;2-A/abstract link to original article] [https://pubmed.ncbi.nlm.nih.gov/7397630 PubMed] | # Cooper MR, Pajak TF, Nissen NI, Stutzman L, Brunner K, Cuttner J, Falkson G, Grunwald H, Bank A, Leone L, Seligman BR, Silver RT, Weiss RB, Haurani F, Blom J, Spurr CL, Glidewell OJ, Gottlieb AJ, Holland JF. A new effective four-drug combination of CCNU (1-[2-chloroethyl]-3-cyclohexyl-1-nitrosourea) (NSC-79038), vinblastine, prednisone, and procarbazine for the treatment of advanced Hodgkin's disease. Cancer. 1980 Aug 15;46(4):654-62. [https://onlinelibrary.wiley.com/doi/10.1002/1097-0142(19800815)46:4%3C654::AID-CNCR2820460405%3E3.0.CO;2-A/abstract link to original article] [https://pubmed.ncbi.nlm.nih.gov/7397630 PubMed] | ||
− | |||
==COPP/ABVD {{#subobject:92a2c8|Regimen=1}}== | ==COPP/ABVD {{#subobject:92a2c8|Regimen=1}}== | ||
{| class="wikitable" style="float:right; margin-left: 5px;" | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
Line 187: | Line 173: | ||
<br>C-MOPP/ABVD: '''<u>C</u>'''yclophospha'''<u>M</u>'''ide, '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rocarbazine, '''<u>P</u>'''rednisone alternating with '''<u>A</u>'''driamycin (Doxorubicin), '''<u>B</u>'''leomycin, '''<u>V</u>'''inblastine, '''<u>D</u>'''acarbazine | <br>C-MOPP/ABVD: '''<u>C</u>'''yclophospha'''<u>M</u>'''ide, '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rocarbazine, '''<u>P</u>'''rednisone alternating with '''<u>A</u>'''driamycin (Doxorubicin), '''<u>B</u>'''leomycin, '''<u>V</u>'''inblastine, '''<u>D</u>'''acarbazine | ||
===Protocol variant #1, 4 cycles {{#subobject:771e81|Variant=1}}=== | ===Protocol variant #1, 4 cycles {{#subobject:771e81|Variant=1}}=== | ||
− | {| class="wikitable sortable" style="width: 100%; text-align:center;" | + | {| class="wikitable sortable" style="width: 100%; text-align:center;" |
!style="width: 20%"|Study | !style="width: 20%"|Study | ||
!style="width: 20%"|Years of enrollment | !style="width: 20%"|Years of enrollment | ||
Line 218: | Line 204: | ||
*[[Procarbazine (Matulane)]] | *[[Procarbazine (Matulane)]] | ||
*[[Prednisone (Sterapred)]] | *[[Prednisone (Sterapred)]] | ||
− | + | '''28-day cycle for 2 total cycles of COPP, alternating with 2 total cycles of ABVD''' | |
− | '''28-day cycle for 2 total cycles of COPP, alternating with 2 total cycles of ABVD''' | ||
− | |||
====Chemotherapy, ABVD portion==== | ====Chemotherapy, ABVD portion==== | ||
*[[Doxorubicin (Adriamycin)]] | *[[Doxorubicin (Adriamycin)]] | ||
Line 226: | Line 210: | ||
*[[Vinblastine (Velban)]] | *[[Vinblastine (Velban)]] | ||
*[[Dacarbazine (DTIC)]] | *[[Dacarbazine (DTIC)]] | ||
− | + | '''28-day cycle for 2 total cycles of ABVD, alternating with 2 total cycles of COPP''' | |
− | '''28-day cycle for 2 total cycles of ABVD, alternating with 2 total cycles of COPP''' | ||
====Subsequent treatment==== | ====Subsequent treatment==== | ||
*GHSG HD5 & HD6: [[Hodgkin_lymphoma#Radiation_therapy_2|EFRT]] | *GHSG HD5 & HD6: [[Hodgkin_lymphoma#Radiation_therapy_2|EFRT]] | ||
*GHSG HD8: [[Hodgkin_lymphoma#Radiation_therapy_2|EFRT]] versus [[Hodgkin_lymphoma#Radiation_therapy_2|IFRT]] | *GHSG HD8: [[Hodgkin_lymphoma#Radiation_therapy_2|EFRT]] versus [[Hodgkin_lymphoma#Radiation_therapy_2|IFRT]] | ||
− | |||
===Protocol variant #2, 6 cycles {{#subobject:6d7f98|Variant=1}}=== | ===Protocol variant #2, 6 cycles {{#subobject:6d7f98|Variant=1}}=== | ||
− | {| class="wikitable" style="width: 40%; text-align:center;" | + | {| class="wikitable" style="width: 40%; text-align:center;" |
!style="width: 25%"|Study | !style="width: 25%"|Study | ||
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]] | !style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
Line 246: | Line 228: | ||
*[[Procarbazine (Matulane)]] | *[[Procarbazine (Matulane)]] | ||
*[[Prednisone (Sterapred)]] | *[[Prednisone (Sterapred)]] | ||
− | + | '''28-day cycle for 3 total cycles of COPP, alternating with 3 total cycles of ABVD''' | |
− | '''28-day cycle for 3 total cycles of COPP, alternating with 3 total cycles of ABVD''' | ||
− | |||
====Chemotherapy, ABVD portion==== | ====Chemotherapy, ABVD portion==== | ||
*[[Doxorubicin (Adriamycin)]] | *[[Doxorubicin (Adriamycin)]] | ||
Line 254: | Line 234: | ||
*[[Vinblastine (Velban)]] | *[[Vinblastine (Velban)]] | ||
*[[Dacarbazine (DTIC)]] | *[[Dacarbazine (DTIC)]] | ||
− | + | '''28-day cycle for 3 total cycles of ABVD, alternating with 3 total cycles of COPP''' | |
− | '''28-day cycle for 3 total cycles of ABVD, alternating with 3 total cycles of COPP''' | ||
====Subsequent treatment==== | ====Subsequent treatment==== | ||
*COPP/ABVD x 1 (8 cycles total) versus IFRT | *COPP/ABVD x 1 (8 cycles total) versus IFRT | ||
− | |||
===Protocol variant #3, 10 cycles {{#subobject:faa63|Variant=1}}=== | ===Protocol variant #3, 10 cycles {{#subobject:faa63|Variant=1}}=== | ||
− | {| class="wikitable sortable" style="width: 100%; text-align:center;" | + | {| class="wikitable sortable" style="width: 100%; text-align:center;" |
!style="width: 20%"|Study | !style="width: 20%"|Study | ||
!style="width: 20%"|Years of enrollment | !style="width: 20%"|Years of enrollment | ||
Line 267: | Line 245: | ||
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | !style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
|- | |- | ||
− | |[ | + | |[https://jjco.oxfordjournals.org/content/30/3/146.long Takenaka et al. 2000 (JCOG 8905)] |
|1989-1993 | |1989-1993 | ||
|style="background-color:#91cf61"|Phase II | |style="background-color:#91cf61"|Phase II | ||
Line 291: | Line 269: | ||
*[[Procarbazine (Matulane)]] 100 mg/m<sup>2</sup> (maximum dose of 150 mg) PO once per day on days 1 to 14 | *[[Procarbazine (Matulane)]] 100 mg/m<sup>2</sup> (maximum dose of 150 mg) PO once per day on days 1 to 14 | ||
*[[Prednisone (Sterapred)]] 40 mg/m<sup>2</sup> PO once per day on days 1 to 3, 8 to 10 | *[[Prednisone (Sterapred)]] 40 mg/m<sup>2</sup> PO once per day on days 1 to 3, 8 to 10 | ||
− | |||
'''28-day cycle for 5 total cycles of COPP, alternating with 5 total cycles of ABVD''' | '''28-day cycle for 5 total cycles of COPP, alternating with 5 total cycles of ABVD''' | ||
− | |||
====Chemotherapy, ABVD portion==== | ====Chemotherapy, ABVD portion==== | ||
*[[Doxorubicin (Adriamycin)]] 25 mg/m<sup>2</sup> IV once per day on days 1 & 15 | *[[Doxorubicin (Adriamycin)]] 25 mg/m<sup>2</sup> IV once per day on days 1 & 15 | ||
Line 299: | Line 275: | ||
*[[Vinblastine (Velban)]] 6 mg/m<sup>2</sup> (maximum of 10 mg per dose) IV once per day on days 1 & 15 | *[[Vinblastine (Velban)]] 6 mg/m<sup>2</sup> (maximum of 10 mg per dose) IV once per day on days 1 & 15 | ||
*[[Dacarbazine (DTIC)]] 250 mg/m<sup>2</sup> IV once per day on days 1 & 15 | *[[Dacarbazine (DTIC)]] 250 mg/m<sup>2</sup> IV once per day on days 1 & 15 | ||
− | + | '''28-day cycle for 5 total cycles of ABVD, alternating with 5 total cycles of COPP''' | |
− | '''28-day cycle for 5 total cycles of ABVD, alternating with 5 total cycles of COPP''' | ||
====Subsequent treatment==== | ====Subsequent treatment==== | ||
*Some studies: [[Hodgkin_lymphoma#Radiation_therapy_2|IFRT]] x 30 Gy after completion of chemotherapy was given to patients with bulky (at least 10 cm maximum diameter) disease | *Some studies: [[Hodgkin_lymphoma#Radiation_therapy_2|IFRT]] x 30 Gy after completion of chemotherapy was given to patients with bulky (at least 10 cm maximum diameter) disease | ||
− | |||
====Dose modifications==== | ====Dose modifications==== | ||
*Treatment was postponed for at least 1 week or until recovery if: | *Treatment was postponed for at least 1 week or until recovery if: | ||
Line 314: | Line 288: | ||
*Bleomycin was stopped if the PaO2 was less than 70 mmHg or if it decreased more than 10 mmHg from the previous measurement | *Bleomycin was stopped if the PaO2 was less than 70 mmHg or if it decreased more than 10 mmHg from the previous measurement | ||
*Note: Dacarbazine 250 mg/m<sup>2</sup> was used at this dose reduction based on experiences in a pilot study in which there was severe emesis with 375 mg/m<sup>2</sup>. | *Note: Dacarbazine 250 mg/m<sup>2</sup> was used at this dose reduction based on experiences in a pilot study in which there was severe emesis with 375 mg/m<sup>2</sup>. | ||
− | |||
===References=== | ===References=== | ||
# '''GHSG HD3:''' Diehl V, Loeffler M, Pfreundschuh M, Ruehl U, Hasenclever D, Nisters-Backes H, Sieber M, Smith K, Tesch H, Geilen W, Adler M, Bartels H, Brandenburg U, Diezler P, Doelken G, Enzian J, Fuchs R, Gassmann W, Gerhartz H, Hagenaukamp U, Hecht T, Hiller E, Hinkelbein H, Lathan B, Kirchner H, Kuehn G, Kuerten H, Loos U, Makoski B, Oertel W, Petsch S, Pfab R, Pflueger H, Planker M, Rohioff R, Sack H, Samandari S, Sauer R, Schalk K, Schmitz G, Schoppe W, Schwieder G, Szepesi S, Teichmann J, Wilhelmy W, Worst P, Fischer R, Georgii A, Huebner E, Schwarze EW; German Hodgkin's Study Group. Further chemotherapy versus low-dose involved-field radiotherapy as consolidation of complete remission after six cycles of alternating chemotherapy in patients with advance Hodgkin's disease. Ann Oncol. 1995 Nov;6(9):901-10. [https://doi.org/10.1093/oxfordjournals.annonc.a059357 link to original article] [https://pubmed.ncbi.nlm.nih.gov/8624293 PubMed] | # '''GHSG HD3:''' Diehl V, Loeffler M, Pfreundschuh M, Ruehl U, Hasenclever D, Nisters-Backes H, Sieber M, Smith K, Tesch H, Geilen W, Adler M, Bartels H, Brandenburg U, Diezler P, Doelken G, Enzian J, Fuchs R, Gassmann W, Gerhartz H, Hagenaukamp U, Hecht T, Hiller E, Hinkelbein H, Lathan B, Kirchner H, Kuehn G, Kuerten H, Loos U, Makoski B, Oertel W, Petsch S, Pfab R, Pflueger H, Planker M, Rohioff R, Sack H, Samandari S, Sauer R, Schalk K, Schmitz G, Schoppe W, Schwieder G, Szepesi S, Teichmann J, Wilhelmy W, Worst P, Fischer R, Georgii A, Huebner E, Schwarze EW; German Hodgkin's Study Group. Further chemotherapy versus low-dose involved-field radiotherapy as consolidation of complete remission after six cycles of alternating chemotherapy in patients with advance Hodgkin's disease. Ann Oncol. 1995 Nov;6(9):901-10. [https://doi.org/10.1093/oxfordjournals.annonc.a059357 link to original article] [https://pubmed.ncbi.nlm.nih.gov/8624293 PubMed] | ||
Line 321: | Line 294: | ||
## '''Update:''' Engert A, Diehl V, Franklin J, Lohri A, Dörken B, Ludwig WD, Koch P, Hänel M, Pfreundschuh M, Wilhelm M, Trümper L, Aulitzky WE, Bentz M, Rummel M, Sezer O, Müller-Hermelink HK, Hasenclever D, Löffler M. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol. 2009 Sep 20;27(27):4548-54. [https://doi.org/10.1200/jco.2008.19.8820 link to original article] [https://pubmed.ncbi.nlm.nih.gov/19704068 PubMed] | ## '''Update:''' Engert A, Diehl V, Franklin J, Lohri A, Dörken B, Ludwig WD, Koch P, Hänel M, Pfreundschuh M, Wilhelm M, Trümper L, Aulitzky WE, Bentz M, Rummel M, Sezer O, Müller-Hermelink HK, Hasenclever D, Löffler M. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol. 2009 Sep 20;27(27):4548-54. [https://doi.org/10.1200/jco.2008.19.8820 link to original article] [https://pubmed.ncbi.nlm.nih.gov/19704068 PubMed] | ||
## '''Update:''' von Tresckow B, Kreissl S, Dipl-Math HG, Bröckelmann PJ, Pabst T, Fridrik M, Rummel M, Jung W, Thiemer J, Sasse S, Bürkle C, Baues C, Diehl V, Engert A, Borchmann P; German Hodgkin Study Group. Intensive treatment strategies in advanced-stage Hodgkin's lymphoma (HD9 and HD12): analysis of long-term survival in two randomised trials. Lancet Haematol. 2018 Oct 01;5(10):e462-73. [https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(18)30140-6/fulltext link to original article] [https://pubmed.ncbi.nlm.nih.gov/30290903 PubMed] | ## '''Update:''' von Tresckow B, Kreissl S, Dipl-Math HG, Bröckelmann PJ, Pabst T, Fridrik M, Rummel M, Jung W, Thiemer J, Sasse S, Bürkle C, Baues C, Diehl V, Engert A, Borchmann P; German Hodgkin Study Group. Intensive treatment strategies in advanced-stage Hodgkin's lymphoma (HD9 and HD12): analysis of long-term survival in two randomised trials. Lancet Haematol. 2018 Oct 01;5(10):e462-73. [https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(18)30140-6/fulltext link to original article] [https://pubmed.ncbi.nlm.nih.gov/30290903 PubMed] | ||
− | # '''JCOG 8905:''' Takenaka T, Mikuni C, Miura A, Sasaki T, Suzuki H, Hotta T, Hirano M, Fukuhara S, Sugiyama H, Nasu K, Dohi H, Kozuru M, Tomonaga M, Tajima K, Niimi M, Fukuda H, Mukai K, Shimoyama M; Lymphoma Study Group of the Japan Clinical Oncology Group. Alternating combination chemotherapy C-MOPP (cyclophosphamide, vincristine, procarbazine, prednisone) and ABVd (adriamycin, bleomycin, vinblastine, dacarbazine) in clinical stage II-IV Hodgkin's disease: a multicenter phase II study (JCOG 8905). Jpn J Clin Oncol. 2000 Mar;30(3):146-52. [ | + | # '''JCOG 8905:''' Takenaka T, Mikuni C, Miura A, Sasaki T, Suzuki H, Hotta T, Hirano M, Fukuhara S, Sugiyama H, Nasu K, Dohi H, Kozuru M, Tomonaga M, Tajima K, Niimi M, Fukuda H, Mukai K, Shimoyama M; Lymphoma Study Group of the Japan Clinical Oncology Group. Alternating combination chemotherapy C-MOPP (cyclophosphamide, vincristine, procarbazine, prednisone) and ABVd (adriamycin, bleomycin, vinblastine, dacarbazine) in clinical stage II-IV Hodgkin's disease: a multicenter phase II study (JCOG 8905). Jpn J Clin Oncol. 2000 Mar;30(3):146-52. [https://jjco.oxfordjournals.org/content/30/3/146.long link to original article] '''contains protocol''' [https://pubmed.ncbi.nlm.nih.gov/10798542 PubMed] |
# '''GHSG HD5:''' Sieber M, Tesch H, Pfistner B, Rueffer U, Lathan B, Brosteanu O, Paulus U, Koch T, Pfreundschuh M, Loeffler M, Engert A, Josting A, Wolf J, Hasenclever D, Franklin J, Duehmke E, Georgii A, Schalk KP, Kirchner H, Doelken G, Munker R, Koch P, Herrmann R, Greil R, Anselmo AP, Diehl V. Rapidly alternating COPP/ABV/IMEP is not superior to conventional alternating COPP/ABVD in combination with extended-field radiotherapy in intermediate-stage Hodgkin's lymphoma: final results of the German Hodgkin's Lymphoma Study Group Trial HD5. J Clin Oncol. 2002 Jan 15;20(2):476-84. [https://doi.org/10.1200/JCO.2002.20.2.476 link to original article] [https://pubmed.ncbi.nlm.nih.gov/11786577 PubMed] | # '''GHSG HD5:''' Sieber M, Tesch H, Pfistner B, Rueffer U, Lathan B, Brosteanu O, Paulus U, Koch T, Pfreundschuh M, Loeffler M, Engert A, Josting A, Wolf J, Hasenclever D, Franklin J, Duehmke E, Georgii A, Schalk KP, Kirchner H, Doelken G, Munker R, Koch P, Herrmann R, Greil R, Anselmo AP, Diehl V. Rapidly alternating COPP/ABV/IMEP is not superior to conventional alternating COPP/ABVD in combination with extended-field radiotherapy in intermediate-stage Hodgkin's lymphoma: final results of the German Hodgkin's Lymphoma Study Group Trial HD5. J Clin Oncol. 2002 Jan 15;20(2):476-84. [https://doi.org/10.1200/JCO.2002.20.2.476 link to original article] [https://pubmed.ncbi.nlm.nih.gov/11786577 PubMed] | ||
# '''GHSG HD8:''' Engert A, Schiller P, Josting A, Herrmann R, Koch P, Sieber M, Boissevain F, De Wit M, Mezger J, Duhmke E, Willich N, Muller RP, Schmidt BF, Renner H, Muller-Hermelink HK, Pfistner B, Wolf J, Hasenclever D, Loffler M, Diehl V; German Hodgkin's Lymphoma Study Group. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol. 2003 Oct 1;21(19):3601-8. Epub 2003 Aug 11. [https://doi.org/10.1200/JCO.2003.03.023 link to original article] '''contains protocol''' [https://pubmed.ncbi.nlm.nih.gov/12913100 PubMed] | # '''GHSG HD8:''' Engert A, Schiller P, Josting A, Herrmann R, Koch P, Sieber M, Boissevain F, De Wit M, Mezger J, Duhmke E, Willich N, Muller RP, Schmidt BF, Renner H, Muller-Hermelink HK, Pfistner B, Wolf J, Hasenclever D, Loffler M, Diehl V; German Hodgkin's Lymphoma Study Group. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol. 2003 Oct 1;21(19):3601-8. Epub 2003 Aug 11. [https://doi.org/10.1200/JCO.2003.03.023 link to original article] '''contains protocol''' [https://pubmed.ncbi.nlm.nih.gov/12913100 PubMed] | ||
Line 328: | Line 301: | ||
# '''GHSG HD6:''' Sieber M, Tesch H, Pfistner B, Rueffer U, Paulus U, Munker R, Hermann R, Doelken G, Koch P, Oertel J, Roller S, Worst P, Bischof H, Glunz A, Greil R, von Kalle K, Schalk KP, Hasenclever D, Brosteanu O, Duehmke E, Georgii A, Engert A, Loeffler M, Diehl V, Mueller RP, Willich N, Fischer R, Hansmann ML, Stein H, Schober T, Koch B; German Hodgkin's Lymphoma Study Group. Treatment of advanced Hodgkin's disease with COPP/ABV/IMEP versus COPP/ABVD and consolidating radiotherapy: final results of the German Hodgkin's Lymphoma Study Group HD6 trial. Ann Oncol. 2004 Feb;15(2):276-82. [https://doi.org/10.1093/annonc/mdh046 link to original article] [https://pubmed.ncbi.nlm.nih.gov/14760122 PubMed] | # '''GHSG HD6:''' Sieber M, Tesch H, Pfistner B, Rueffer U, Paulus U, Munker R, Hermann R, Doelken G, Koch P, Oertel J, Roller S, Worst P, Bischof H, Glunz A, Greil R, von Kalle K, Schalk KP, Hasenclever D, Brosteanu O, Duehmke E, Georgii A, Engert A, Loeffler M, Diehl V, Mueller RP, Willich N, Fischer R, Hansmann ML, Stein H, Schober T, Koch B; German Hodgkin's Lymphoma Study Group. Treatment of advanced Hodgkin's disease with COPP/ABV/IMEP versus COPP/ABVD and consolidating radiotherapy: final results of the German Hodgkin's Lymphoma Study Group HD6 trial. Ann Oncol. 2004 Feb;15(2):276-82. [https://doi.org/10.1093/annonc/mdh046 link to original article] [https://pubmed.ncbi.nlm.nih.gov/14760122 PubMed] | ||
# '''GHSG HD9elderly:''' Ballova V, Rüffer JU, Haverkamp H, Pfistner B, Müller-Hermelink HK, Dühmke E, Worst P, Wilhelmy M, Naumann R, Hentrich M, Eich HT, Josting A, Löffler M, Diehl V, Engert A. A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin's disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly). Ann Oncol. 2005 Jan;16(1):124-31. [https://doi.org/10.1093/annonc/mdi023 link to original article]'''contains protocol''' [https://pubmed.ncbi.nlm.nih.gov/15598949 PubMed] | # '''GHSG HD9elderly:''' Ballova V, Rüffer JU, Haverkamp H, Pfistner B, Müller-Hermelink HK, Dühmke E, Worst P, Wilhelmy M, Naumann R, Hentrich M, Eich HT, Josting A, Löffler M, Diehl V, Engert A. A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin's disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly). Ann Oncol. 2005 Jan;16(1):124-31. [https://doi.org/10.1093/annonc/mdi023 link to original article]'''contains protocol''' [https://pubmed.ncbi.nlm.nih.gov/15598949 PubMed] | ||
− | |||
==CVPP {{#subobject:be8f99|Regimen=1}}== | ==CVPP {{#subobject:be8f99|Regimen=1}}== | ||
{| class="wikitable" style="float:right; margin-left: 5px;" | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
Line 334: | Line 306: | ||
|[[#top|back to top]] | |[[#top|back to top]] | ||
|} | |} | ||
− | |||
CVPP: '''<u>C</u>'''CNU (Lomustine), '''<u>V</u>'''inblastine, '''<u>P</u>'''rocarbazine, '''<u>P</u>'''rednisone | CVPP: '''<u>C</u>'''CNU (Lomustine), '''<u>V</u>'''inblastine, '''<u>P</u>'''rocarbazine, '''<u>P</u>'''rednisone | ||
− | |||
===Regimen {{#subobject:e71c98|Variant=1}}=== | ===Regimen {{#subobject:e71c98|Variant=1}}=== | ||
− | {| class="wikitable sortable" style="width: 100%; text-align:center;" | + | {| class="wikitable sortable" style="width: 100%; text-align:center;" |
!style="width: 20%"|Study | !style="width: 20%"|Study | ||
!style="width: 20%"|Years of enrollment | !style="width: 20%"|Years of enrollment | ||
Line 382: | Line 352: | ||
*[[Procarbazine (Matulane)]] | *[[Procarbazine (Matulane)]] | ||
*[[Prednisone (Sterapred)]] | *[[Prednisone (Sterapred)]] | ||
− | |||
===References=== | ===References=== | ||
# Cooper MR, Pajak TF, Nissen NI, Stutzman L, Brunner K, Cuttner J, Falkson G, Grunwald H, Bank A, Leone L, Seligman BR, Silver RT, Weiss RB, Haurani F, Blom J, Spurr CL, Glidewell OJ, Gottlieb AJ, Holland JF. A new effective four-drug combination of CCNU (1-[2-chloroethyl]-3-cyclohexyl-1-nitrosourea) (NSC-79038), vinblastine, prednisone, and procarbazine for the treatment of advanced Hodgkin's disease. Cancer. 1980 Aug 15;46(4):654-62. [https://onlinelibrary.wiley.com/doi/10.1002/1097-0142(19800815)46:4%3C654::AID-CNCR2820460405%3E3.0.CO;2-A/abstract link to original article] [https://pubmed.ncbi.nlm.nih.gov/7397630 PubMed] | # Cooper MR, Pajak TF, Nissen NI, Stutzman L, Brunner K, Cuttner J, Falkson G, Grunwald H, Bank A, Leone L, Seligman BR, Silver RT, Weiss RB, Haurani F, Blom J, Spurr CL, Glidewell OJ, Gottlieb AJ, Holland JF. A new effective four-drug combination of CCNU (1-[2-chloroethyl]-3-cyclohexyl-1-nitrosourea) (NSC-79038), vinblastine, prednisone, and procarbazine for the treatment of advanced Hodgkin's disease. Cancer. 1980 Aug 15;46(4):654-62. [https://onlinelibrary.wiley.com/doi/10.1002/1097-0142(19800815)46:4%3C654::AID-CNCR2820460405%3E3.0.CO;2-A/abstract link to original article] [https://pubmed.ncbi.nlm.nih.gov/7397630 PubMed] | ||
Line 389: | Line 358: | ||
# Pavlovsky S, Schvartzman E, Lastiri F, Magnasco H, Corrado C, Raslawski E, Cancela ME, Ardaiz MC, Cerutti I, Rosso A, Bruno S, Aranguren PN, Salvarezza A, Donato H, Dibar E, Zirone S; GATLA. Randomized trial of CVPP for three versus six cycles in favorable-prognosis and CVPP versus AOPE plus radiotherapy in intermediate-prognosis untreated Hodgkin's disease. J Clin Oncol. 1997 Jul;15(7):2652-8. [https://doi.org/10.1200/JCO.1997.15.7.2652 link to original article] [https://pubmed.ncbi.nlm.nih.gov/9215837 PubMed] | # Pavlovsky S, Schvartzman E, Lastiri F, Magnasco H, Corrado C, Raslawski E, Cancela ME, Ardaiz MC, Cerutti I, Rosso A, Bruno S, Aranguren PN, Salvarezza A, Donato H, Dibar E, Zirone S; GATLA. Randomized trial of CVPP for three versus six cycles in favorable-prognosis and CVPP versus AOPE plus radiotherapy in intermediate-prognosis untreated Hodgkin's disease. J Clin Oncol. 1997 Jul;15(7):2652-8. [https://doi.org/10.1200/JCO.1997.15.7.2652 link to original article] [https://pubmed.ncbi.nlm.nih.gov/9215837 PubMed] | ||
# Sackmann-Muriel F, Zubizarreta P, Gallo G, Scopinaro M, Alderete D, Alfaro E, Casak S, Chantada G, Felice MS, Quinteros R. Hodgkin disease in children: results of a prospective randomized trial in a single institution in Argentina. Med Pediatr Oncol. 1997 Dec;29(6):544-52. [https://onlinelibrary.wiley.com/doi/abs/10.1002/(SICI)1096-911X(199712)29:6%3C544::AID-MPO5%3E3.0.CO;2-K link to original article] [https://pubmed.ncbi.nlm.nih.gov/9324342 PubMed] | # Sackmann-Muriel F, Zubizarreta P, Gallo G, Scopinaro M, Alderete D, Alfaro E, Casak S, Chantada G, Felice MS, Quinteros R. Hodgkin disease in children: results of a prospective randomized trial in a single institution in Argentina. Med Pediatr Oncol. 1997 Dec;29(6):544-52. [https://onlinelibrary.wiley.com/doi/abs/10.1002/(SICI)1096-911X(199712)29:6%3C544::AID-MPO5%3E3.0.CO;2-K link to original article] [https://pubmed.ncbi.nlm.nih.gov/9324342 PubMed] | ||
− | |||
==Doxorubicin & Vinblastine {{#subobject:66828f|Regimen=1}}== | ==Doxorubicin & Vinblastine {{#subobject:66828f|Regimen=1}}== | ||
{| class="wikitable" style="float:right; margin-left: 5px;" | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
Line 396: | Line 364: | ||
|} | |} | ||
===Regimen {{#subobject:597e32|Variant=1}}=== | ===Regimen {{#subobject:597e32|Variant=1}}=== | ||
− | {| class="wikitable sortable" style="width: 100%; text-align:center;" | + | {| class="wikitable sortable" style="width: 100%; text-align:center;" |
!style="width: 20%"|Study | !style="width: 20%"|Study | ||
!style="width: 20%"|Years of enrollment | !style="width: 20%"|Years of enrollment | ||
Line 414: | Line 382: | ||
*[[Doxorubicin (Adriamycin)]] 25 mg/m<sup>2</sup> IV once per day on days 1 & 15 | *[[Doxorubicin (Adriamycin)]] 25 mg/m<sup>2</sup> IV once per day on days 1 & 15 | ||
*[[Vinblastine (Velban)]] 6 mg/m<sup>2</sup> IV once per day on days 1 & 15 | *[[Vinblastine (Velban)]] 6 mg/m<sup>2</sup> IV once per day on days 1 & 15 | ||
− | |||
'''28-day cycle for 3 cycles''' | '''28-day cycle for 3 cycles''' | ||
====Subsequent treatment==== | ====Subsequent treatment==== | ||
*STLI | *STLI | ||
− | |||
===References=== | ===References=== | ||
# '''SWOG S9133:''' Press OW, LeBlanc M, Lichter AS, Grogan TM, Unger JM, Wasserman TH, Gaynor ER, Peterson BA, Miller TP, Fisher RI. Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin's disease. J Clin Oncol. 2001 Nov 15;19(22):4238-44. [https://doi.org/10.1200/JCO.2001.19.22.4238 link to original article] '''contains verified protocol''' [https://pubmed.ncbi.nlm.nih.gov/11709567 PubMed] NCT00002495 | # '''SWOG S9133:''' Press OW, LeBlanc M, Lichter AS, Grogan TM, Unger JM, Wasserman TH, Gaynor ER, Peterson BA, Miller TP, Fisher RI. Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin's disease. J Clin Oncol. 2001 Nov 15;19(22):4238-44. [https://doi.org/10.1200/JCO.2001.19.22.4238 link to original article] '''contains verified protocol''' [https://pubmed.ncbi.nlm.nih.gov/11709567 PubMed] NCT00002495 | ||
− | |||
==LOPP {{#subobject:f2a168|Regimen=1}}== | ==LOPP {{#subobject:f2a168|Regimen=1}}== | ||
{| class="wikitable" style="float:right; margin-left: 5px;" | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
Line 429: | Line 394: | ||
LOPP: '''<u>L</u>'''eukeran (Chlorambucil), '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rocarbazine, '''<u>P</u>'''rednisone | LOPP: '''<u>L</u>'''eukeran (Chlorambucil), '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rocarbazine, '''<u>P</u>'''rednisone | ||
===Regimen {{#subobject:bfcf5a|Variant=1}}=== | ===Regimen {{#subobject:bfcf5a|Variant=1}}=== | ||
− | {| class="wikitable sortable" style="width: 100%; text-align:center;" | + | {| class="wikitable sortable" style="width: 100%; text-align:center;" |
!style="width: 20%"|Study | !style="width: 20%"|Study | ||
!style="width: 20%"|Years of enrollment | !style="width: 20%"|Years of enrollment | ||
Line 458: | Line 423: | ||
## '''Update:''' Hancock BW, Vaughan Hudson G, Vaughan Hudson B, Haybittle JL, Bennett MH, MacLennan KA, Jelliffe AM; BNLI. British National Lymphoma Investigation randomised study of MOPP (mustine, Oncovin, procarbazine, prednisolone) against LOPP (Leukeran substituted for mustine) in advanced Hodgkin's disease--long term results. Br J Cancer. 1991 Apr;63(4):579-82. [https://doi.org/10.1038/bjc.1991.134 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1972355/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/2021542 PubMed] | ## '''Update:''' Hancock BW, Vaughan Hudson G, Vaughan Hudson B, Haybittle JL, Bennett MH, MacLennan KA, Jelliffe AM; BNLI. British National Lymphoma Investigation randomised study of MOPP (mustine, Oncovin, procarbazine, prednisolone) against LOPP (Leukeran substituted for mustine) in advanced Hodgkin's disease--long term results. Br J Cancer. 1991 Apr;63(4):579-82. [https://doi.org/10.1038/bjc.1991.134 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1972355/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/2021542 PubMed] | ||
# Hancock BW, Vaughan Hudson G, Vaughan Hudson B, Bennett MH, MacLennan KA, Haybittle JL, Anderson L, Linch DC; BNLI. LOPP alternating with EVAP is superior to LOPP alone in the initial treatment of advanced Hodgkin's disease: results of a British National Lymphoma Investigation trial. J Clin Oncol. 1992 Aug;10(8):1252-8. [https://doi.org/10.1200/JCO.1992.10.8.1252 link to original article] [https://pubmed.ncbi.nlm.nih.gov/1634914 PubMed] | # Hancock BW, Vaughan Hudson G, Vaughan Hudson B, Bennett MH, MacLennan KA, Haybittle JL, Anderson L, Linch DC; BNLI. LOPP alternating with EVAP is superior to LOPP alone in the initial treatment of advanced Hodgkin's disease: results of a British National Lymphoma Investigation trial. J Clin Oncol. 1992 Aug;10(8):1252-8. [https://doi.org/10.1200/JCO.1992.10.8.1252 link to original article] [https://pubmed.ncbi.nlm.nih.gov/1634914 PubMed] | ||
− | |||
==LOPP/EVAP {{#subobject:22b023|Regimen=1}}== | ==LOPP/EVAP {{#subobject:22b023|Regimen=1}}== | ||
{| class="wikitable" style="float:right; margin-left: 5px;" | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
Line 466: | Line 430: | ||
LOPP/EVAP: '''<u>L</u>'''eukeran (Chlorambucil), '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rocarbazine, '''<u>P</u>'''rednisone alternating with '''<u>E</u>'''toposide, '''<u>V</u>'''inblastine, '''<u>A</u>'''driamycin (Doxorubicin), '''<u>P</u>'''rednisone | LOPP/EVAP: '''<u>L</u>'''eukeran (Chlorambucil), '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rocarbazine, '''<u>P</u>'''rednisone alternating with '''<u>E</u>'''toposide, '''<u>V</u>'''inblastine, '''<u>A</u>'''driamycin (Doxorubicin), '''<u>P</u>'''rednisone | ||
===Protocol {{#subobject:53f4da|Variant=1}}=== | ===Protocol {{#subobject:53f4da|Variant=1}}=== | ||
− | {| class="wikitable sortable" style="width: 100%; text-align:center;" | + | {| class="wikitable sortable" style="width: 100%; text-align:center;" |
!style="width: 20%"|Study | !style="width: 20%"|Study | ||
!style="width: 20%"|Years of enrollment | !style="width: 20%"|Years of enrollment | ||
Line 499: | Line 463: | ||
# Hancock BW, Vaughan Hudson G, Vaughan Hudson B, Bennett MH, MacLennan KA, Haybittle JL, Anderson L, Linch DC; BNLI. LOPP alternating with EVAP is superior to LOPP alone in the initial treatment of advanced Hodgkin's disease: results of a British National Lymphoma Investigation trial. J Clin Oncol. 1992 Aug;10(8):1252-8. [https://doi.org/10.1200/JCO.1992.10.8.1252 link to original article] [https://pubmed.ncbi.nlm.nih.gov/1634914 PubMed] | # Hancock BW, Vaughan Hudson G, Vaughan Hudson B, Bennett MH, MacLennan KA, Haybittle JL, Anderson L, Linch DC; BNLI. LOPP alternating with EVAP is superior to LOPP alone in the initial treatment of advanced Hodgkin's disease: results of a British National Lymphoma Investigation trial. J Clin Oncol. 1992 Aug;10(8):1252-8. [https://doi.org/10.1200/JCO.1992.10.8.1252 link to original article] [https://pubmed.ncbi.nlm.nih.gov/1634914 PubMed] | ||
# Hancock BW, Vaughan Hudson G, Vaughan Hudson B, Linch DC, Anderson L, MacLennan KA; BNLI. Hybrid LOPP/EVA is not better than LOPP alternating with EVAP: a prematurely terminated British National Lymphoma Investigation randomized trial. Ann Oncol. 1994;5 Suppl 2:117-20. [https://doi.org/10.1093/annonc/5.suppl_2.s117 link to original article] [https://pubmed.ncbi.nlm.nih.gov/8204511 PubMed] | # Hancock BW, Vaughan Hudson G, Vaughan Hudson B, Linch DC, Anderson L, MacLennan KA; BNLI. Hybrid LOPP/EVA is not better than LOPP alternating with EVAP: a prematurely terminated British National Lymphoma Investigation randomized trial. Ann Oncol. 1994;5 Suppl 2:117-20. [https://doi.org/10.1093/annonc/5.suppl_2.s117 link to original article] [https://pubmed.ncbi.nlm.nih.gov/8204511 PubMed] | ||
− | |||
==Mechlorethamine monotherapy {{#subobject:3674c2|Regimen=1}}== | ==Mechlorethamine monotherapy {{#subobject:3674c2|Regimen=1}}== | ||
{| class="wikitable" style="float:right; margin-left: 5px;" | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
Line 506: | Line 469: | ||
|} | |} | ||
===Regimen {{#subobject:2761c1|Variant=1}}=== | ===Regimen {{#subobject:2761c1|Variant=1}}=== | ||
− | {| class="wikitable sortable" style="width: 100%; text-align:center;" | + | {| class="wikitable sortable" style="width: 100%; text-align:center;" |
!style="width: 20%"|Study | !style="width: 20%"|Study | ||
!style="width: 20%"|Years of enrollment | !style="width: 20%"|Years of enrollment | ||
Line 513: | Line 476: | ||
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | !style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
|- | |- | ||
− | |[ | + | |[https://jamanetwork.com/journals/jama/fullarticle/288442 Goodman et al. 1946] |
|NR | |NR | ||
| style="background-color:#91cf61" |Non-randomized | | style="background-color:#91cf61" |Non-randomized | ||
Line 548: | Line 511: | ||
*[[Mechlorethamine (Mustargen)]] | *[[Mechlorethamine (Mustargen)]] | ||
===References=== | ===References=== | ||
− | # Goodman LS, Wintrobe MM, Dameshek W, Goodman MJ, Gilman A, McLennan MT. Nitrogen mustard therapy; use of methyl-bis (beta-chloroethyl) amine hydrochloride and tris (beta-chloroethyl) amine hydrochloride for Hodgkin's disease, lymphosarcoma, leukemia and certain allied and miscellaneous disorders. J Am Med Assoc. 1946 Sep 21;132:126-32. [ | + | # Goodman LS, Wintrobe MM, Dameshek W, Goodman MJ, Gilman A, McLennan MT. Nitrogen mustard therapy; use of methyl-bis (beta-chloroethyl) amine hydrochloride and tris (beta-chloroethyl) amine hydrochloride for Hodgkin's disease, lymphosarcoma, leukemia and certain allied and miscellaneous disorders. J Am Med Assoc. 1946 Sep 21;132:126-32. [https://jamanetwork.com/journals/jama/fullarticle/288442 link to original article] [https://pubmed.ncbi.nlm.nih.gov/20997191 PubMed] |
# Jacobson LO, Spurr CL, Guzman-Barron ES, Smith T, Lushbaugh C, Dick GF. Nitrogen mustard therapy; studies on the effect of methyl-bis (beta-chloroethyl) amine hydrochloride on neoplastic diseases and allied disorders of the hemopoietic system. J Am Med Assoc. 1946 Oct 5;132:263-71. [https://jamanetwork.com/journals/jama/article-abstract/288767 link to original article] [https://pubmed.ncbi.nlm.nih.gov/20997209 PubMed] | # Jacobson LO, Spurr CL, Guzman-Barron ES, Smith T, Lushbaugh C, Dick GF. Nitrogen mustard therapy; studies on the effect of methyl-bis (beta-chloroethyl) amine hydrochloride on neoplastic diseases and allied disorders of the hemopoietic system. J Am Med Assoc. 1946 Oct 5;132:263-71. [https://jamanetwork.com/journals/jama/article-abstract/288767 link to original article] [https://pubmed.ncbi.nlm.nih.gov/20997209 PubMed] | ||
# Wintrobe MM, Huguley CM Jr, McLennan MT, Penna de Carvalho Lima L. Nitrogen mustard as a therapeutic agent for Hodgkin's disease, lymphosarcoma and leukemia. Ann Intern Med. 1947 Oct;27(4):529-40. [http://annals.org/aim/article/673669/nitrogen-mustard-therapeutic-agent-hodgkin-s-disease-lymphosarcoma-leukemia link to original article] [https://pubmed.ncbi.nlm.nih.gov/20268426 PubMed] | # Wintrobe MM, Huguley CM Jr, McLennan MT, Penna de Carvalho Lima L. Nitrogen mustard as a therapeutic agent for Hodgkin's disease, lymphosarcoma and leukemia. Ann Intern Med. 1947 Oct;27(4):529-40. [http://annals.org/aim/article/673669/nitrogen-mustard-therapeutic-agent-hodgkin-s-disease-lymphosarcoma-leukemia link to original article] [https://pubmed.ncbi.nlm.nih.gov/20268426 PubMed] | ||
# Meyer AH, Overmiller WC. The use of nitrogen mustard in Hodgkin's disease and lymphosarcoma. Ann Intern Med. 1949 Feb;30(2):381-6. [http://annals.org/aim/article/673986/use-nitrogen-mustard-hodgkin-s-disease-lymphosarcoma link to original article] [https://pubmed.ncbi.nlm.nih.gov/18109292 PubMed] | # Meyer AH, Overmiller WC. The use of nitrogen mustard in Hodgkin's disease and lymphosarcoma. Ann Intern Med. 1949 Feb;30(2):381-6. [http://annals.org/aim/article/673986/use-nitrogen-mustard-hodgkin-s-disease-lymphosarcoma link to original article] [https://pubmed.ncbi.nlm.nih.gov/18109292 PubMed] | ||
# Jacobs EM, Peters FC, Luce JK, Zippin C, Wood DA. Mechlorethamine HCl and cyclophosphamide in the treatment of Hodgkin's disease and the lymphomas. JAMA. 1968 Feb 5;203(6):392-8. [https://jamanetwork.com/journals/jama/article-abstract/337835 link to original article] [https://pubmed.ncbi.nlm.nih.gov/4865234 PubMed] | # Jacobs EM, Peters FC, Luce JK, Zippin C, Wood DA. Mechlorethamine HCl and cyclophosphamide in the treatment of Hodgkin's disease and the lymphomas. JAMA. 1968 Feb 5;203(6):392-8. [https://jamanetwork.com/journals/jama/article-abstract/337835 link to original article] [https://pubmed.ncbi.nlm.nih.gov/4865234 PubMed] | ||
− | |||
==MOPP/ABVD {{#subobject:f28468|Regimen=1}}== | ==MOPP/ABVD {{#subobject:f28468|Regimen=1}}== | ||
{| class="wikitable" style="float:right; margin-left: 5px;" | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
Line 560: | Line 522: | ||
|} | |} | ||
MOPP/ABVD: '''<u>M</u>'''ustargen (Mechlorethamine), '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rocarbazine, '''<u>P</u>'''rednisone alternating with '''<u>A</u>'''driamycin (Doxorubicin), '''<u>B</u>'''leomycin, '''<u>V</u>'''inblastine, '''<u>D</u>'''acarbazine | MOPP/ABVD: '''<u>M</u>'''ustargen (Mechlorethamine), '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rocarbazine, '''<u>P</u>'''rednisone alternating with '''<u>A</u>'''driamycin (Doxorubicin), '''<u>B</u>'''leomycin, '''<u>V</u>'''inblastine, '''<u>D</u>'''acarbazine | ||
− | |||
===Protocol {{#subobject:5b28f5|Variant=1}}=== | ===Protocol {{#subobject:5b28f5|Variant=1}}=== | ||
− | {| class="wikitable sortable" style="width: 100%; text-align:center;" | + | {| class="wikitable sortable" style="width: 100%; text-align:center;" |
!style="width: 20%"|Study | !style="width: 20%"|Study | ||
!style="width: 20%"|Years of enrollment | !style="width: 20%"|Years of enrollment | ||
Line 630: | Line 591: | ||
# '''NCIC-CTG HD4:''' Connors JM, Klimo P, Adams G, Burns BF, Cooper I, Meyer RM, O'Reilly SE, Pater J, Quirt I, Sadura A, Shustik C, Skillings J, Sutcliffe S, Verma S, Yoshida S, Zee B. Treatment of advanced Hodgkin's disease with chemotherapy--comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: a report from the National Cancer Institute of Canada clinical trials group. J Clin Oncol. 1997 Apr;15(4):1638-45. Erratum in: J Clin Oncol 1997 Jul;15(7):2762. [https://doi.org/10.1200/jco.1997.15.4.1638 link to original article] [https://pubmed.ncbi.nlm.nih.gov/9193364 PubMed] | # '''NCIC-CTG HD4:''' Connors JM, Klimo P, Adams G, Burns BF, Cooper I, Meyer RM, O'Reilly SE, Pater J, Quirt I, Sadura A, Shustik C, Skillings J, Sutcliffe S, Verma S, Yoshida S, Zee B. Treatment of advanced Hodgkin's disease with chemotherapy--comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: a report from the National Cancer Institute of Canada clinical trials group. J Clin Oncol. 1997 Apr;15(4):1638-45. Erratum in: J Clin Oncol 1997 Jul;15(7):2762. [https://doi.org/10.1200/jco.1997.15.4.1638 link to original article] [https://pubmed.ncbi.nlm.nih.gov/9193364 PubMed] | ||
# '''CCG-521:''' Hutchinson RJ, Fryer CJ, Davis PC, Nachman J, Krailo MD, O'Brien RT, Collins RD, Whalen T, Reardon D, Trigg ME, Gilchrist GS. MOPP or radiation in addition to ABVD in the treatment of pathologically staged advanced Hodgkin's disease in children: results of the Children's Cancer Group Phase III Trial. J Clin Oncol. 1998 Mar;16(3):897-906. [https://doi.org/10.1200/JCO.1998.16.3.897 link to original article] [https://pubmed.ncbi.nlm.nih.gov/9508171 PubMed] | # '''CCG-521:''' Hutchinson RJ, Fryer CJ, Davis PC, Nachman J, Krailo MD, O'Brien RT, Collins RD, Whalen T, Reardon D, Trigg ME, Gilchrist GS. MOPP or radiation in addition to ABVD in the treatment of pathologically staged advanced Hodgkin's disease in children: results of the Children's Cancer Group Phase III Trial. J Clin Oncol. 1998 Mar;16(3):897-906. [https://doi.org/10.1200/JCO.1998.16.3.897 link to original article] [https://pubmed.ncbi.nlm.nih.gov/9508171 PubMed] | ||
− | |||
==MVPP {{#subobject:b01f3a|Regimen=1}}== | ==MVPP {{#subobject:b01f3a|Regimen=1}}== | ||
{| class="wikitable" style="float:right; margin-left: 5px;" | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
Line 636: | Line 596: | ||
|[[#top|back to top]] | |[[#top|back to top]] | ||
|} | |} | ||
− | |||
MVPP: '''<u>M</u>'''echlorethamine, '''<u>V</u>'''inblastine, '''<u>P</u>'''rocarbazine, '''<u>P</u>'''rednisone | MVPP: '''<u>M</u>'''echlorethamine, '''<u>V</u>'''inblastine, '''<u>P</u>'''rocarbazine, '''<u>P</u>'''rednisone | ||
− | |||
===Regimen {{#subobject:312fd8|Variant=1}}=== | ===Regimen {{#subobject:312fd8|Variant=1}}=== | ||
− | {| class="wikitable sortable" style="width: 100%; text-align:center;" | + | {| class="wikitable sortable" style="width: 100%; text-align:center;" |
!style="width: 20%"|Study | !style="width: 20%"|Study | ||
!style="width: 20%"|Years of enrollment | !style="width: 20%"|Years of enrollment | ||
Line 665: | Line 623: | ||
*[[Procarbazine (Matulane)]] | *[[Procarbazine (Matulane)]] | ||
*[[Prednisone (Sterapred)]] | *[[Prednisone (Sterapred)]] | ||
− | |||
===References=== | ===References=== | ||
# Cooper MR, Pajak TF, Nissen NI, Stutzman L, Brunner K, Cuttner J, Falkson G, Grunwald H, Bank A, Leone L, Seligman BR, Silver RT, Weiss RB, Haurani F, Blom J, Spurr CL, Glidewell OJ, Gottlieb AJ, Holland JF. A new effective four-drug combination of CCNU (1-[2-chloroethyl]-3-cyclohexyl-1-nitrosourea) (NSC-79038), vinblastine, prednisone, and procarbazine for the treatment of advanced Hodgkin's disease. Cancer. 1980 Aug 15;46(4):654-62. [https://onlinelibrary.wiley.com/doi/10.1002/1097-0142(19800815)46:4%3C654::AID-CNCR2820460405%3E3.0.CO;2-A/abstract link to original article] [https://pubmed.ncbi.nlm.nih.gov/7397630 PubMed] | # Cooper MR, Pajak TF, Nissen NI, Stutzman L, Brunner K, Cuttner J, Falkson G, Grunwald H, Bank A, Leone L, Seligman BR, Silver RT, Weiss RB, Haurani F, Blom J, Spurr CL, Glidewell OJ, Gottlieb AJ, Holland JF. A new effective four-drug combination of CCNU (1-[2-chloroethyl]-3-cyclohexyl-1-nitrosourea) (NSC-79038), vinblastine, prednisone, and procarbazine for the treatment of advanced Hodgkin's disease. Cancer. 1980 Aug 15;46(4):654-62. [https://onlinelibrary.wiley.com/doi/10.1002/1097-0142(19800815)46:4%3C654::AID-CNCR2820460405%3E3.0.CO;2-A/abstract link to original article] [https://pubmed.ncbi.nlm.nih.gov/7397630 PubMed] | ||
− | |||
==NOVP {{#subobject:230457|Regimen=1}}== | ==NOVP {{#subobject:230457|Regimen=1}}== | ||
{| class="wikitable" style="float:right; margin-left: 5px;" | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
Line 676: | Line 632: | ||
NOVP: '''<u>N</u>'''ovantrone (Mitoxantrone), '''<u>O</u>'''ncovin (Vincristine), '''<u>V</u>'''inblastine, '''<u>P</u>'''rednisone | NOVP: '''<u>N</u>'''ovantrone (Mitoxantrone), '''<u>O</u>'''ncovin (Vincristine), '''<u>V</u>'''inblastine, '''<u>P</u>'''rednisone | ||
===Regimen {{#subobject:5bf81f|Variant=1}}=== | ===Regimen {{#subobject:5bf81f|Variant=1}}=== | ||
− | {| class="wikitable" style="width: 40%; text-align:center;" | + | {| class="wikitable" style="width: 40%; text-align:center;" |
!style="width: 25%"|Study | !style="width: 25%"|Study | ||
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]] | !style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
Line 689: | Line 645: | ||
*[[Vinblastine (Velban)]] | *[[Vinblastine (Velban)]] | ||
*[[Prednisone (Sterapred)]] | *[[Prednisone (Sterapred)]] | ||
− | |||
===References=== | ===References=== | ||
# Hagemeister FB, Cabanillas F, Velásquez WS, Meistrich ML, Liang JC, McLaughlin P, Redman JR, Romaguera JE, Rodríguez MA, Swan F Jr, Fuller LM. NOVP: a novel chemotherapeutic regimen with minimal toxicity for treatment of Hodgkin's disease. Semin Oncol. 1990 Dec;17(6 Suppl 10):34-8. [http://www.seminoncol.org/article/0093-7754(90)90122-J/abstract link to original article] [https://pubmed.ncbi.nlm.nih.gov/2259922 PubMed] | # Hagemeister FB, Cabanillas F, Velásquez WS, Meistrich ML, Liang JC, McLaughlin P, Redman JR, Romaguera JE, Rodríguez MA, Swan F Jr, Fuller LM. NOVP: a novel chemotherapeutic regimen with minimal toxicity for treatment of Hodgkin's disease. Semin Oncol. 1990 Dec;17(6 Suppl 10):34-8. [http://www.seminoncol.org/article/0093-7754(90)90122-J/abstract link to original article] [https://pubmed.ncbi.nlm.nih.gov/2259922 PubMed] | ||
− | |||
==SCAB {{#subobject:344883|Regimen=1}}== | ==SCAB {{#subobject:344883|Regimen=1}}== | ||
{| class="wikitable" style="float:right; margin-left: 5px;" | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
Line 698: | Line 652: | ||
|[[#top|back to top]] | |[[#top|back to top]] | ||
|} | |} | ||
− | |||
SCAB: '''<u>S</u>'''treptozocin, '''<u>C</u>'''CNU (Lomustine), '''<u>A</u>'''driamycin (Doxorubicin), '''<u>B</u>'''leomycin | SCAB: '''<u>S</u>'''treptozocin, '''<u>C</u>'''CNU (Lomustine), '''<u>A</u>'''driamycin (Doxorubicin), '''<u>B</u>'''leomycin | ||
− | |||
===Regimen {{#subobject:a68d3b|Variant=1}}=== | ===Regimen {{#subobject:a68d3b|Variant=1}}=== | ||
− | {| class="wikitable" style="width: 40%; text-align:center;" | + | {| class="wikitable" style="width: 40%; text-align:center;" |
!style="width: 25%"|Study | !style="width: 25%"|Study | ||
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]] | !style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]] | ||
Line 715: | Line 667: | ||
*[[Doxorubicin (Adriamycin)]] | *[[Doxorubicin (Adriamycin)]] | ||
*[[Bleomycin (Blenoxane)]] | *[[Bleomycin (Blenoxane)]] | ||
− | |||
===References=== | ===References=== | ||
# Diggs CH, Wiernik PH, Sutherland JC. Treatment of advanced untreated Hodgkin's disease with SCAB--an alternative to MOPP. Cancer. 1981 Jan 15;47(2):224-8. [https://onlinelibrary.wiley.com/doi/10.1002/1097-0142(19810115)47:2%3C224::AID-CNCR2820470203%3E3.0.CO;2-6/abstract link to original article] [https://pubmed.ncbi.nlm.nih.gov/6161689 PubMed] | # Diggs CH, Wiernik PH, Sutherland JC. Treatment of advanced untreated Hodgkin's disease with SCAB--an alternative to MOPP. Cancer. 1981 Jan 15;47(2):224-8. [https://onlinelibrary.wiley.com/doi/10.1002/1097-0142(19810115)47:2%3C224::AID-CNCR2820470203%3E3.0.CO;2-6/abstract link to original article] [https://pubmed.ncbi.nlm.nih.gov/6161689 PubMed] | ||
## '''Update:''' Wiernik PH, Schiffer CA. Long-term follow-up of advanced Hodgkin's disease patients treated with a combination of streptozotocin, lomustine (CCNU), doxorubicin and bleomycin (SCAB). J Cancer Res Clin Oncol. 1988;114(1):105-7. [https://doi.org/10.1007/bf00390494 link to original article] [https://pubmed.ncbi.nlm.nih.gov/2450876 PubMed] | ## '''Update:''' Wiernik PH, Schiffer CA. Long-term follow-up of advanced Hodgkin's disease patients treated with a combination of streptozotocin, lomustine (CCNU), doxorubicin and bleomycin (SCAB). J Cancer Res Clin Oncol. 1988;114(1):105-7. [https://doi.org/10.1007/bf00390494 link to original article] [https://pubmed.ncbi.nlm.nih.gov/2450876 PubMed] | ||
− | |||
==Vinblastine monotherapy {{#subobject:b1c2da|Regimen=1}}== | ==Vinblastine monotherapy {{#subobject:b1c2da|Regimen=1}}== | ||
{| class="wikitable" style="float:right; margin-left: 5px;" | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
Line 726: | Line 676: | ||
|} | |} | ||
===Regimen {{#subobject:48bfd8|Variant=1}}=== | ===Regimen {{#subobject:48bfd8|Variant=1}}=== | ||
− | {| class="wikitable sortable" style="width: 100%; text-align:center;" | + | {| class="wikitable sortable" style="width: 100%; text-align:center;" |
!style="width: 20%"|Study | !style="width: 20%"|Study | ||
!style="width: 20%"|Years of enrollment | !style="width: 20%"|Years of enrollment | ||
Line 742: | Line 692: | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
*[[Vinblastine (Velban)]] | *[[Vinblastine (Velban)]] | ||
+ | ===References=== | ||
+ | # Stutzman L, Ezdinli EZ, Stutzman MA. Vinblastine sulfate vs cyclophosphamide in the therapy for lymphoma. JAMA. 1966 Jan 17;195(3):173-8. [https://jamanetwork.com/journals/jama/article-abstract/657749 link to original article] [https://pubmed.ncbi.nlm.nih.gov/5322863 PubMed] | ||
+ | ==OPPA {{#subobject:6418c0|Regimen=1}}== | ||
+ | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
+ | |- | ||
+ | |[[#top|back to top]] | ||
+ | |} | ||
+ | OPPA: '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rocarbazine, '''<u>P</u>'''rednisone, '''<u>A</u>'''driamycin (Doxorubicin) | ||
+ | ===Regimen {{#subobject:e17569|Variant=1}}=== | ||
+ | {| class="wikitable sortable" style="width: 60%; text-align:center;" | ||
+ | ! style="width: 33%" |Study | ||
+ | ! style="width: 33%" |Years of enrollment | ||
+ | ! style="width: 33%" |[[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | |- | ||
+ | |[https://doi.org/10.1200/jco.2009.26.9381 Mauz-Körholz et al. 2010 (GPOH-HD-2002)] | ||
+ | |2002-2005 | ||
+ | | style="background-color:#91cf61" | Phase II | ||
+ | |- | ||
+ | |} | ||
+ | ''This regimen is meant for girls. Patients with early-stage disease only received the OPPA portion, see text for details.'' | ||
+ | ====Chemotherapy==== | ||
+ | *[[Vincristine (Oncovin)]] 1.5 mg/m<sup>2</sup> IV once per day on days 1, 8, 15 | ||
+ | *[[Procarbazine (Matulane)]] 100 mg/m<sup>2</sup> PO once per day on days 1 to 15 | ||
+ | *[[Prednisone (Sterapred)]] 60 mg/m<sup>2</sup> PO once per day on days 1 to 15 | ||
+ | *[[Doxorubicin (Adriamycin)]] 40 mg/m<sup>2</sup> IV once per day on days 1 & 15 | ||
+ | '''28-day cycle for 2 cycles''' | ||
+ | ====Subsequent treatment==== | ||
+ | *Treatment group 2: [[#C-MOPP|COPP]] x 2 | ||
+ | *Treatment group 3: [[#C-MOPP|COPP]] x 4 | ||
+ | ===References=== | ||
+ | #'''GPOH-HD-2002:''' Mauz-Körholz C, Hasenclever D, Dörffel W, Ruschke K, Pelz T, Voigt A, Stiefel M, Winkler M, Vilser C, Dieckmann K, Karlén J, Bergsträsser E, Fosså A, Mann G, Hummel M, Klapper W, Stein H, Vordermark D, Kluge R, Körholz D. Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin's lymphoma: the GPOH-HD-2002 study. J Clin Oncol. 2010 Aug 10;28(23):3680-6. Epub 2010 Jul 12. [https://doi.org/10.1200/jco.2009.26.9381 link to original article] '''contains verified protocol''' [https://pubmed.ncbi.nlm.nih.gov/20625128 PubMed] NCT00416832 | ||
+ | ==VAMP (Methotrexate) {{#subobject:4d666a|Regimen=1}}== | ||
+ | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
+ | |- | ||
+ | |[[#top|back to top]] | ||
+ | |} | ||
+ | VAMP: '''<u>V</u>'''inblastine, '''<u>A</u>'''driamycin (Doxorubicin), '''<u>M</u>'''ethrotrexate, '''<u>P</u>'''rednisone | ||
+ | ===Regimen {{#subobject:6f694d|Variant=1}}=== | ||
+ | {| class="wikitable" style="width: 40%; text-align:center;" | ||
+ | ! style="width: 25%" |Study | ||
+ | ! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | |- | ||
+ | |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3526806/ Metzger et al. 2012 (HOD99)] | ||
+ | | style="background-color:#91cf61" |Phase 2 | ||
+ | |- | ||
+ | |} | ||
+ | ''To be completed? This is to be distinguished from the VAMP protocols used in AML and multiple myeloma.'' | ||
+ | ====Chemotherapy==== | ||
+ | *[[Vinblastine (Velban)]] | ||
+ | *[[Doxorubicin (Adriamycin)]] | ||
+ | *[[Methotrexate (MTX)]] | ||
+ | *[[Prednisone (Sterapred)]] | ||
+ | '''4 cycles''' | ||
+ | ====Subsequent treatment==== | ||
+ | *Early responders: [[Hodgkin_lymphoma_-_null_regimens#Observation|Observation]] versus [[#Radiation_therapy_2|RT]] | ||
+ | ===References=== | ||
+ | #'''HOD99:''' Metzger ML, Weinstein HJ, Hudson MM, Billett AL, Larsen EC, Friedmann A, Howard SC, Donaldson SS, Krasin MJ, Kun LE, Marcus KJ, Yock TI, Tarbell N, Billups CA, Wu J, Link MP. Association between radiotherapy vs no radiotherapy based on early response to VAMP chemotherapy and survival among children with favorable-risk Hodgkin lymphoma. JAMA. 2012 Jun 27;307(24):2609-16. [https://jamanetwork.com/journals/jama/fullarticle/1199151 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3526806/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/22735430 PubMed] | ||
+ | ==ABVE {{#subobject:c24h71|Regimen=1}}== | ||
+ | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
+ | |- | ||
+ | |[[#top|back to top]] | ||
+ | |} | ||
+ | ABVE: '''<u>A</u>'''driamycin (Doxorubicin), '''<u>B</u>'''leomycin, '''<u>V</u>'''incristine, '''<u>E</u>'''toposide | ||
+ | ===Regimen {{#subobject:7fa7ya|Variant=1}}=== | ||
+ | {| class="wikitable sortable" style="width: 60%; text-align:center;" | ||
+ | ! style="width: 33%" |Study | ||
+ | ! style="width: 33%" |Years of enrollment | ||
+ | ! style="width: 33%" |[[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | |- | ||
+ | |[https://www.ncbi.nlm.nih.gov/pmc/articles/pmc3468662/ Tebbi et al. 2012 (POG P9426)] | ||
+ | |1996-2001 | ||
+ | | style="background-color:#91cf61" |Non-randomized (see note) | ||
+ | |- | ||
+ | |} | ||
+ | ''Note: this trial had a randomization to receive or not receive dexrazoxane. Labeled here as non-randomized because this drug does not have antineoplastic properties.'' | ||
+ | ====Chemotherapy==== | ||
+ | *[[Doxorubicin (Adriamycin)]] 25 mg/m<sup>2</sup> IV once per day on days 1 & 15 | ||
+ | *[[Bleomycin (Blenoxane)]] 10 units/m<sup>2</sup> IV once per day on days 1 & 15 | ||
+ | *[[Vincristine (Oncovin)]] 1.5 mg/m<sup>2</sup> (maximum dose of 2 mg) IV once per day on days 1 & 15 | ||
+ | *[[Etoposide (Vepesid)]] 100 mg/m<sup>2</sup> IV once per day on days 1 to 5 | ||
+ | ====Supportive medications==== | ||
+ | *[[Filgrastim (Neupogen)]] 5 mcg/kg SC once per day on days 6 to 14, then once per day on days 16 until ANC greater than 1000/uL | ||
+ | '''28-day cycle for 2 cycles''' | ||
+ | ====Subsequent treatment==== | ||
+ | *CR: [[#Radiation_therapy_2|IFRT consolidation]] | ||
+ | *Other than CR: [[#ABVE|ABVE]] x 2, then [[#Radiation_therapy_2|IFRT consolidation]] | ||
+ | ===References=== | ||
+ | #'''POG P9426:''' Tebbi CK, Mendenhall NP, London WB, Williams JL, Hutchison RE, Fitzgerald TJ, de Alarcón PA, Schwartz C, Chauvenet A. Response-dependent and reduced treatment in lower risk Hodgkin lymphoma in children and adolescents, results of P9426: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2012 Dec 15;59(7):1259-65. Epub 2012 Aug 21. [https://doi.org/10.1002/pbc.24279 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc3468662/ link to PMC article] '''contains verified protocol''' [https://pubmed.ncbi.nlm.nih.gov/22911615/ PubMed] NCT00002827 | ||
+ | ==MOPP {{#subobject:bcde0|Regimen=1}}== | ||
+ | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
+ | |- | ||
+ | |[[#top|back to top]] | ||
+ | |} | ||
+ | MOPP: '''<u>M</u>'''echlorethamine, '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rocarbazine, '''<u>P</u>'''rednisone | ||
+ | ===Regimen variant #3, uncapped vincristine {{#subobject:ff7478|Variant=1}}=== | ||
+ | {| class="wikitable sortable" style="width: 100%; text-align:center;" | ||
+ | ! style="width: 20%" |Study | ||
+ | ! style="width: 20%" |Years of enrollment | ||
+ | ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | ! style="width: 20%" |Comparator | ||
+ | ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
+ | |- | ||
+ | |[http://www.bloodjournal.org/content/42/2/163.long Young et al. 1973a] | ||
+ | |1964-NR | ||
+ | | style="background-color:#91cf61" |Non-randomized (RT) | ||
+ | | style="background-color:#d3d3d3" | | ||
+ | | style="background-color:#d3d3d3" | | ||
+ | |- | ||
+ | |[https://onlinelibrary.wiley.com/doi/abs/10.1002/1097-0142(197610)38:4%3C1494::AID-CNCR2820380408%3E3.0.CO;2-E Kolygin 1976] | ||
+ | |1970-1975 | ||
+ | | style="background-color:#91cf61" |Non-randomized (RT) | ||
+ | | style="background-color:#d3d3d3" | | ||
+ | | style="background-color:#d3d3d3" | | ||
+ | |- | ||
+ | |} | ||
+ | ==== Chemotherapy==== | ||
+ | *[[Mechlorethamine (Mustargen)]] 6 mg/m<sup>2</sup> IV once per day on days 1 & 8 | ||
+ | *[[Vincristine (Oncovin)]] 1.4 mg/m<sup>2</sup> IV once per day on days 1 & 8 | ||
+ | *[[Procarbazine (Matulane)]] 100 mg/m<sup>2</sup> PO once per day on days 1 to 14 | ||
+ | *[[Prednisone (Sterapred)]] 40 mg/m<sup>2</sup> PO once per day on days 1 to 14 | ||
+ | '''28-day cycle for 6 to 8 cycles''' | ||
+ | ===References=== | ||
+ | #Young RC, DeVita VT, Johnson RE. Hodgkin's disease in childhood. Blood. 1973 Aug;42(2):163-74. [http://www.bloodjournal.org/content/42/2/163.long link to original article] [https://pubmed.ncbi.nlm.nih.gov/4793108 PubMed] | ||
+ | #Kolygin BA. Combination chemotherapy of Hodgkin's disease in children. Cancer. 1976 Oct;38(4):1494-7. [https://onlinelibrary.wiley.com/doi/abs/10.1002/1097-0142(197610)38:4%3C1494::AID-CNCR2820380408%3E3.0.CO;2-E link to original article] [https://pubmed.ncbi.nlm.nih.gov/991072 PubMed] | ||
+ | |||
+ | =Consolidation after upfront therapy= | ||
+ | ==C-MOPP {{#subobject:034931|Regimen=1}}== | ||
+ | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
+ | |- | ||
+ | |[[#top|back to top]] | ||
+ | |} | ||
+ | C-MOPP: '''<u>C</u>'''yclophospha'''<u>M</u>'''ide, '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rocarbazine, '''<u>P</u>'''rednisone | ||
+ | <br>COPP: '''<u>C</u>'''yclophosphamide, '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rocarbazine, '''<u>P</u>'''rednisone | ||
+ | ===Regimen variant #1, 2 cycles {{#subobject:cfcc4b|Variant=1}}=== | ||
+ | {| class="wikitable sortable" style="width: 60%; text-align:center;" | ||
+ | ! style="width: 33%" |Study | ||
+ | ! style="width: 33%" |Years of enrollment | ||
+ | ! style="width: 33%" |[[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | |- | ||
+ | |[https://doi.org/10.1200/jco.2009.26.9381 Mauz-Körholz et al. 2010 (GPOH-HD-2002)] | ||
+ | |2002-2005 | ||
+ | | style="background-color:#91cf61" |Phase II | ||
+ | |- | ||
+ | |} | ||
+ | ====Preceding treatment==== | ||
+ | *[[#OPPA|OPPA]] x 2 | ||
+ | ====Chemotherapy==== | ||
+ | *[[Cyclophosphamide (Cytoxan)]] 500 mg/m<sup>2</sup> IV once per day on days 1 & 8 | ||
+ | *[[Vincristine (Oncovin)]] 1.5 mg/m<sup>2</sup> IV once per day on days 1 & 8 | ||
+ | *[[Prednisone (Sterapred)]] 40 mg/m<sup>2</sup> PO once per day on days 1 to 15 | ||
+ | *[[Procarbazine (Matulane)]] 100 mg/m<sup>2</sup> PO once per day on days 1 to 15 | ||
+ | '''28-day cycle for 2 cycles''' | ||
+ | ===Regimen variant #2, 4 cycles {{#subobject:228db9|Variant=1}}=== | ||
+ | {| class="wikitable sortable" style="width: 60%; text-align:center;" | ||
+ | ! style="width: 33%" |Study | ||
+ | ! style="width: 33%" |Years of enrollment | ||
+ | ! style="width: 33%" |[[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | |- | ||
+ | |[https://doi.org/10.1200/jco.2009.26.9381 Mauz-Körholz et al. 2010 (GPOH-HD-2002)] | ||
+ | |2002-2005 | ||
+ | | style="background-color:#91cf61" |Phase II | ||
+ | |- | ||
+ | |} | ||
+ | ====Preceding treatment==== | ||
+ | *[[#OPPA|OPPA]] x 2 | ||
+ | ====Chemotherapy==== | ||
+ | *[[Cyclophosphamide (Cytoxan)]] 500 mg/m<sup>2</sup> IV once per day on days 1 & 8 | ||
+ | *[[Vincristine (Oncovin)]] 1.5 mg/m<sup>2</sup> IV once per day on days 1 & 8 | ||
+ | *[[Prednisone (Sterapred)]] 40 mg/m<sup>2</sup> PO once per day on days 1 to 15 | ||
+ | *[[Procarbazine (Matulane)]] 100 mg/m<sup>2</sup> PO once per day on days 1 to 15 | ||
+ | '''28-day cycle for 4 cycles''' | ||
===References=== | ===References=== | ||
− | # | + | #'''GPOH-HD-2002:''' Mauz-Körholz C, Hasenclever D, Dörffel W, Ruschke K, Pelz T, Voigt A, Stiefel M, Winkler M, Vilser C, Dieckmann K, Karlén J, Bergsträsser E, Fosså A, Mann G, Hummel M, Klapper W, Stein H, Vordermark D, Kluge R, Körholz D. Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin's lymphoma: the GPOH-HD-2002 study. J Clin Oncol. 2010 Aug 10;28(23):3680-6. Epub 2010 Jul 12. [https://doi.org/10.1200/jco.2009.26.9381 link to original article] '''contains verified protocol''' [https://pubmed.ncbi.nlm.nih.gov/20625128 PubMed] NCT00416832 |
+ | ==COPDAC {{#subobject:195ad7|Regimen=1}}== | ||
+ | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
+ | |- | ||
+ | |[[#top|back to top]] | ||
+ | |} | ||
+ | COPDAC: '''<u>C</u>'''yclophosphamide, '''<u>O</u>'''ncovin (Vincristine), '''<u>P</u>'''rednisone, '''<u>DAC</u>'''arbazine | ||
+ | ===Regimen variant #1, 2 cycles {{#subobject:e9d06d|Variant=1}}=== | ||
+ | {| class="wikitable sortable" style="width: 60%; text-align:center;" | ||
+ | ! style="width: 33%" |Study | ||
+ | ! style="width: 33%" |Years of enrollment | ||
+ | ! style="width: 33%" |[[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | |- | ||
+ | |[https://doi.org/10.1200/jco.2009.26.9381 Mauz-Körholz et al. 2010 (GPOH-HD-2002)] | ||
+ | |2002-2005 | ||
+ | | style="background-color:#91cf61" |Phase II | ||
+ | |- | ||
+ | |} | ||
+ | ====Preceding treatment==== | ||
+ | *[[#OEPA|OEPA]] x 2 | ||
+ | ====Chemotherapy==== | ||
+ | *[[Cyclophosphamide (Cytoxan)]] 500 mg/m<sup>2</sup> IV once per day on days 1 & 8 | ||
+ | *[[Vincristine (Oncovin)]] 1.5 mg/m<sup>2</sup> IV once per day on days 1 & 8 | ||
+ | *[[Prednisone (Sterapred)]] 40 mg/m<sup>2</sup> PO once per day on days 1 to 15 | ||
+ | *[[Dacarbazine (DTIC)]] 250 mg/m<sup>2</sup> IV once per day on days 1 to 4 | ||
+ | '''28-day cycle for 2 cycles''' | ||
+ | ===Regimen variant #2, 4 cycles {{#subobject:515d30|Variant=1}}=== | ||
+ | {| class="wikitable sortable" style="width: 60%; text-align:center;" | ||
+ | ! style="width: 33%" |Study | ||
+ | ! style="width: 33%" |Years of enrollment | ||
+ | ! style="width: 33%" |[[Levels_of_Evidence#Evidence|Evidence]] | ||
+ | |- | ||
+ | |[https://doi.org/10.1200/jco.2009.26.9381 Mauz-Körholz et al. 2010 (GPOH-HD-2002)] | ||
+ | |2002-2005 | ||
+ | | style="background-color:#91cf61" |Phase II | ||
+ | |- | ||
+ | |} | ||
+ | ====Preceding treatment==== | ||
+ | *[[#OEPA|OEPA]] x 2 | ||
+ | ==== Chemotherapy==== | ||
+ | *[[Cyclophosphamide (Cytoxan)]] 500 mg/m<sup>2</sup> IV once per day on days 1 & 8 | ||
+ | *[[Vincristine (Oncovin)]] 1.5 mg/m<sup>2</sup> IV once per day on days 1 & 8 | ||
+ | *[[Prednisone (Sterapred)]] 40 mg/m<sup>2</sup> PO once per day on days 1 to 15 | ||
+ | *[[Dacarbazine (DTIC)]] 250 mg/m<sup>2</sup> IV once per day on days 1 to 4 | ||
+ | '''28-day cycle for 4 cycles''' | ||
+ | ===References === | ||
+ | #'''GPOH-HD-2002:''' Mauz-Körholz C, Hasenclever D, Dörffel W, Ruschke K, Pelz T, Voigt A, Stiefel M, Winkler M, Vilser C, Dieckmann K, Karlén J, Bergsträsser E, Fosså A, Mann G, Hummel M, Klapper W, Stein H, Vordermark D, Kluge R, Körholz D. Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin's lymphoma: the GPOH-HD-2002 study. J Clin Oncol. 2010 Aug 10;28(23):3680-6. Epub 2010 Jul 12. [https://doi.org/10.1200/jco.2009.26.9381 link to original article] '''contains verified protocol''' [https://pubmed.ncbi.nlm.nih.gov/20625128 PubMed] NCT00416832 | ||
+ | |||
=Maintenance after upfront therapy= | =Maintenance after upfront therapy= | ||
Line 753: | Line 921: | ||
|} | |} | ||
===Regimen {{#subobject:52ca75|Variant=1}}=== | ===Regimen {{#subobject:52ca75|Variant=1}}=== | ||
− | {| class="wikitable sortable" style="width: 100%; text-align:center;" | + | {| class="wikitable sortable" style="width: 100%; text-align:center;" |
− | !style="width: 20%"|Study | + | ! style="width: 20%" |Study |
− | !style="width: 20%"|Years of enrollment | + | ! style="width: 20%" |Years of enrollment |
− | !style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]] | + | ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]] |
− | !style="width: 20%"|Comparator | + | ! style="width: 20%" |Comparator |
− | !style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | + | ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] |
|- | |- | ||
|[https://www.nejm.org/doi/full/10.1056/NEJM197412052912305 Sokal et al. 1974] | |[https://www.nejm.org/doi/full/10.1056/NEJM197412052912305 Sokal et al. 1974] | ||
|1965-1967 | |1965-1967 | ||
− | |style="background-color:#91cf61"|Randomized, <20 pts in this subgroup (E-esc) | + | | style="background-color:#91cf61" |Randomized, <20 pts in this subgroup (E-esc) |
|[[Hodgkin_lymphoma_-_null_regimens#Observation_2|Observation]] | |[[Hodgkin_lymphoma_-_null_regimens#Observation_2|Observation]] | ||
− | |style="background-color:#1a9850"|Superior PFS | + | | style="background-color:#1a9850" |Superior PFS |
|- | |- | ||
|} | |} | ||
''Note: this study was open to patients with "malignant lymphoma" but the majority had Hodgkin disease.'' | ''Note: this study was open to patients with "malignant lymphoma" but the majority had Hodgkin disease.'' | ||
− | ====Immunotherapy==== | + | ==== Immunotherapy==== |
*[[Bacillus Calmette-Guérin (BCG)]] | *[[Bacillus Calmette-Guérin (BCG)]] | ||
===References=== | ===References=== | ||
− | # Sokal JE, Aungst CW, Snyderman M. Delay in progression of malignant lymphoma after BCG vaccination. N Engl J Med. 1974 Dec 5;291(23):1226-30. [https://www.nejm.org/doi/full/10.1056/NEJM197412052912305 link to original article] [https://pubmed.ncbi.nlm.nih.gov/4609380 PubMed] | + | #Sokal JE, Aungst CW, Snyderman M. Delay in progression of malignant lymphoma after BCG vaccination. N Engl J Med. 1974 Dec 5;291(23):1226-30. [https://www.nejm.org/doi/full/10.1056/NEJM197412052912305 link to original article] [https://pubmed.ncbi.nlm.nih.gov/4609380 PubMed] |
− | + | =Relapsed or refractory, salvage therapy = | |
− | =Relapsed or refractory, salvage therapy= | ||
− | |||
==ABDIC {{#subobject:c5c5ab|Regimen=1}}== | ==ABDIC {{#subobject:c5c5ab|Regimen=1}}== | ||
{| class="wikitable" style="float:right; margin-left: 5px;" | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
Line 781: | Line 947: | ||
|} | |} | ||
ABDIC: '''<u>A</u>'''driamycin (Doxorubicin), '''<u>B</u>'''leomycin, '''<u>DI</u>'''C (Dacarbazine), '''<u>C</u>'''CNU (Lomustine), Prednisone | ABDIC: '''<u>A</u>'''driamycin (Doxorubicin), '''<u>B</u>'''leomycin, '''<u>DI</u>'''C (Dacarbazine), '''<u>C</u>'''CNU (Lomustine), Prednisone | ||
− | |||
===Regimen {{#subobject:4ba1e1|Variant=1}}=== | ===Regimen {{#subobject:4ba1e1|Variant=1}}=== | ||
− | {| class="wikitable" style="width: 40%; text-align:center;" | + | {| class="wikitable" style="width: 40%; text-align:center;" |
− | !style="width: 25%"|Study | + | ! style="width: 25%" |Study |
− | !style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]] | + | ! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]] |
|- | |- | ||
|[https://onlinelibrary.wiley.com/doi/10.1002/1097-0142(19801201)46:11%3C2349::AID-CNCR2820461105%3E3.0.CO;2-V/abstract Rodgers et al. 1980] | |[https://onlinelibrary.wiley.com/doi/10.1002/1097-0142(19801201)46:11%3C2349::AID-CNCR2820461105%3E3.0.CO;2-V/abstract Rodgers et al. 1980] | ||
− | |style="background-color:#91cf61"|Phase II | + | | style="background-color:#91cf61" |Phase II |
|- | |- | ||
|} | |} | ||
Line 797: | Line 962: | ||
*[[Lomustine (CCNU)]] | *[[Lomustine (CCNU)]] | ||
*[[Prednisone (Sterapred)]] | *[[Prednisone (Sterapred)]] | ||
− | |||
===References=== | ===References=== | ||
− | # Rodgers RW, Gamble JF, Loh KK, Shullenberger CC. Adriamycin, bleomycin, DIC, CCNU, and prednisone (ABDIC) chemotherapy in MOPP-resistant Hodgkin's disease. Cancer. 1980 Dec 1;46(11):2349-55. [https://onlinelibrary.wiley.com/doi/10.1002/1097-0142(19801201)46:11%3C2349::AID-CNCR2820461105%3E3.0.CO;2-V/abstract link to original article] [https://pubmed.ncbi.nlm.nih.gov/6159961 PubMed] | + | #Rodgers RW, Gamble JF, Loh KK, Shullenberger CC. Adriamycin, bleomycin, DIC, CCNU, and prednisone (ABDIC) chemotherapy in MOPP-resistant Hodgkin's disease. Cancer. 1980 Dec 1;46(11):2349-55. [https://onlinelibrary.wiley.com/doi/10.1002/1097-0142(19801201)46:11%3C2349::AID-CNCR2820461105%3E3.0.CO;2-V/abstract link to original article] [https://pubmed.ncbi.nlm.nih.gov/6159961 PubMed] |
− | ## '''Update:''' Tannir N, Hagemeister F, Velasquez W, Cabanillas F. Long-term follow-up with ABDIC salvage chemotherapy of MOPP-resistant Hodgkin's disease. J Clin Oncol. 1983 Jul;1(7):432-9. [https://doi.org/10.1200/jco.1983.1.7.432 link to original article] [https://pubmed.ncbi.nlm.nih.gov/6199478 PubMed] | + | ##'''Update:''' Tannir N, Hagemeister F, Velasquez W, Cabanillas F. Long-term follow-up with ABDIC salvage chemotherapy of MOPP-resistant Hodgkin's disease. J Clin Oncol. 1983 Jul;1(7):432-9. [https://doi.org/10.1200/jco.1983.1.7.432 link to original article] [https://pubmed.ncbi.nlm.nih.gov/6199478 PubMed] |
− | |||
==ABVD {{#subobject:c5a35d|Regimen=1}}== | ==ABVD {{#subobject:c5a35d|Regimen=1}}== | ||
{| class="wikitable" style="float:right; margin-left: 5px;" | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
Line 808: | Line 971: | ||
|} | |} | ||
ABVD: '''<u>A</u>'''driamycin (Doxorubicin), '''<u>B</u>'''leomycin, '''<u>V</u>'''inblastine, '''<u>D</u>'''acarbazine | ABVD: '''<u>A</u>'''driamycin (Doxorubicin), '''<u>B</u>'''leomycin, '''<u>V</u>'''inblastine, '''<u>D</u>'''acarbazine | ||
− | |||
===Regimen {{#subobject:ae32ee|Variant=1}}=== | ===Regimen {{#subobject:ae32ee|Variant=1}}=== | ||
− | {| class="wikitable" style="width: 40%; text-align:center;" | + | {| class="wikitable" style="width: 40%; text-align:center;" |
− | !style="width: 25%"|Study | + | ! style="width: 25%" | Study |
− | !style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]] | + | ! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]] |
|- | |- | ||
|[https://onlinelibrary.wiley.com/doi/10.1002/1097-0142(197806)41:6%3C2107::AID-CNCR2820410606%3E3.0.CO;2-L/abstract Krikorian et al. 1978] | |[https://onlinelibrary.wiley.com/doi/10.1002/1097-0142(197806)41:6%3C2107::AID-CNCR2820410606%3E3.0.CO;2-L/abstract Krikorian et al. 1978] | ||
− | |style="background-color:#91cf61"|Phase II | + | | style="background-color:#91cf61" |Phase II |
|- | |- | ||
|[https://doi.org/10.1007/bf00254081 Santoro & Bonadonna 1979] | |[https://doi.org/10.1007/bf00254081 Santoro & Bonadonna 1979] | ||
− | |style="background-color:#91cf61"|Non-randomized | + | | style="background-color:#91cf61" | Non-randomized |
|- | |- | ||
|[http://annals.org/article.aspx?articleid=695320 Santoro et al. 1982a] | |[http://annals.org/article.aspx?articleid=695320 Santoro et al. 1982a] | ||
− | |style="background-color:#91cf61"|Non-randomized | + | | style="background-color:#91cf61" |Non-randomized |
|- | |- | ||
|[http://annals.org/article.aspx?articleid=698987 Harker et al. 1984] | |[http://annals.org/article.aspx?articleid=698987 Harker et al. 1984] | ||
− | |style="background-color:#91cf61"|Non-randomized | + | | style="background-color:#91cf61" |Non-randomized |
|- | |- | ||
|} | |} | ||
''This is for historical interest only; ABVD is no longer used in the salvage setting.'' | ''This is for historical interest only; ABVD is no longer used in the salvage setting.'' | ||
− | ====Chemotherapy==== | + | ====Chemotherapy ==== |
*[[Doxorubicin (Adriamycin)]] | *[[Doxorubicin (Adriamycin)]] | ||
*[[Bleomycin (Blenoxane)]] | *[[Bleomycin (Blenoxane)]] | ||
*[[Vinblastine (Velban)]] | *[[Vinblastine (Velban)]] | ||
*[[Dacarbazine (DTIC)]] | *[[Dacarbazine (DTIC)]] | ||
− | |||
===References=== | ===References=== | ||
− | # Krikorian JG, Portlock CS, Rosenberg SA. Treatment of advanced Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide (ABVD) after failure of MOPP therapy. Cancer. 1978 Jun;41(6):2107-11. [https://onlinelibrary.wiley.com/doi/10.1002/1097-0142(197806)41:6%3C2107::AID-CNCR2820410606%3E3.0.CO;2-L/abstract link to original article] [https://pubmed.ncbi.nlm.nih.gov/77716 PubMed] | + | #Krikorian JG, Portlock CS, Rosenberg SA. Treatment of advanced Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide (ABVD) after failure of MOPP therapy. Cancer. 1978 Jun;41(6):2107-11. [https://onlinelibrary.wiley.com/doi/10.1002/1097-0142(197806)41:6%3C2107::AID-CNCR2820410606%3E3.0.CO;2-L/abstract link to original article] [https://pubmed.ncbi.nlm.nih.gov/77716 PubMed] |
− | # Santoro A, Bonadonna G. Prolonged disease-free survival in MOPP-resistant Hodgkin's disease after treatment with adriamycin, bleomycin, vinblastine and dacarbazine (ABVD). Cancer Chemother Pharmacol. 1979;2(2):101-5. [https://doi.org/10.1007/bf00254081 link to original article] [https://pubmed.ncbi.nlm.nih.gov/93984 PubMed] | + | #Santoro A, Bonadonna G. Prolonged disease-free survival in MOPP-resistant Hodgkin's disease after treatment with adriamycin, bleomycin, vinblastine and dacarbazine (ABVD). Cancer Chemother Pharmacol. 1979;2(2):101-5. [https://doi.org/10.1007/bf00254081 link to original article] [https://pubmed.ncbi.nlm.nih.gov/93984 PubMed] |
− | # Santoro A, Bonfante V, Bonadonna G. Salvage chemotherapy with ABVD in MOPP-resistant Hodgkin's disease. Ann Intern Med. 1982 Feb;96(2):139-43. [http://annals.org/article.aspx?articleid=695320 link to original article] [https://pubmed.ncbi.nlm.nih.gov/6174060 PubMed] | + | #Santoro A, Bonfante V, Bonadonna G. Salvage chemotherapy with ABVD in MOPP-resistant Hodgkin's disease. Ann Intern Med. 1982 Feb;96(2):139-43. [http://annals.org/article.aspx?articleid=695320 link to original article] [https://pubmed.ncbi.nlm.nih.gov/6174060 PubMed] |
− | # Harker WG, Kushlan P, Rosenberg SA. Combination chemotherapy for advanced Hodgkin's disease after failure of MOPP: ABVD and B-CAVe. Ann Intern Med. 1984 Oct;101(4):440-6. [http://annals.org/article.aspx?articleid=698987 link to original article] [https://pubmed.ncbi.nlm.nih.gov/6206757 PubMed] | + | #Harker WG, Kushlan P, Rosenberg SA. Combination chemotherapy for advanced Hodgkin's disease after failure of MOPP: ABVD and B-CAVe. Ann Intern Med. 1984 Oct;101(4):440-6. [http://annals.org/article.aspx?articleid=698987 link to original article] [https://pubmed.ncbi.nlm.nih.gov/6206757 PubMed] |
− | |||
==B-CAVe {{#subobject:41a31c|Regimen=1}}== | ==B-CAVe {{#subobject:41a31c|Regimen=1}}== | ||
{| class="wikitable" style="float:right; margin-left: 5px;" | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
Line 846: | Line 1,006: | ||
|} | |} | ||
B-CAVe: '''<u>B</u>'''leomycin, '''<u>C</u>'''CNU (Lomustine), '''<u>A</u>'''driamycin (Doxorubicin), '''<u>V</u>'''inblastin'''<u>e</u>''' | B-CAVe: '''<u>B</u>'''leomycin, '''<u>C</u>'''CNU (Lomustine), '''<u>A</u>'''driamycin (Doxorubicin), '''<u>V</u>'''inblastin'''<u>e</u>''' | ||
− | |||
===Regimen {{#subobject:c53f0c|Variant=1}}=== | ===Regimen {{#subobject:c53f0c|Variant=1}}=== | ||
− | {| class="wikitable" style="width: 40%; text-align:center;" | + | {| class="wikitable" style="width: 40%; text-align:center;" |
− | !style="width: 25%"|Study | + | ! style="width: 25%" |Study |
− | !style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]] | + | ! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]] |
|- | |- | ||
|[https://onlinelibrary.wiley.com/doi/10.1002/1097-0142(197805)41:5%3C1670::AID-CNCR2820410504%3E3.0.CO;2-Y/abstract Porzig et al. 1978] | |[https://onlinelibrary.wiley.com/doi/10.1002/1097-0142(197805)41:5%3C1670::AID-CNCR2820410504%3E3.0.CO;2-Y/abstract Porzig et al. 1978] | ||
− | |style="background-color:#91cf61"|Non-randomized | + | | style="background-color:#91cf61" |Non-randomized |
|- | |- | ||
|[http://annals.org/article.aspx?articleid=698987 Harker et al. 1984] | |[http://annals.org/article.aspx?articleid=698987 Harker et al. 1984] | ||
− | |style="background-color:#91cf61"|Non-randomized | + | | style="background-color:#91cf61" |Non-randomized |
|- | |- | ||
|} | |} | ||
Line 864: | Line 1,023: | ||
*[[Doxorubicin (Adriamycin)]] | *[[Doxorubicin (Adriamycin)]] | ||
*[[Vinblastine (Velban)]] | *[[Vinblastine (Velban)]] | ||
− | |||
===References=== | ===References=== | ||
− | # Porzig KJ, Portlock CS, Robertson A, Rosenberg SA. Treatment of advanced Hodgkin's disease with B-CAVE following MOPP failure. Cancer. 1978 May;41(5):1670-5. [https://onlinelibrary.wiley.com/doi/10.1002/1097-0142(197805)41:5%3C1670::AID-CNCR2820410504%3E3.0.CO;2-Y/abstract link to original article] [https://pubmed.ncbi.nlm.nih.gov/77180 PubMed] | + | #Porzig KJ, Portlock CS, Robertson A, Rosenberg SA. Treatment of advanced Hodgkin's disease with B-CAVE following MOPP failure. Cancer. 1978 May;41(5):1670-5. [https://onlinelibrary.wiley.com/doi/10.1002/1097-0142(197805)41:5%3C1670::AID-CNCR2820410504%3E3.0.CO;2-Y/abstract link to original article] [https://pubmed.ncbi.nlm.nih.gov/77180 PubMed] |
− | # Harker WG, Kushlan P, Rosenberg SA. Combination chemotherapy for advanced Hodgkin's disease after failure of MOPP: ABVD and B-CAVe. Ann Intern Med. 1984 Oct;101(4):440-6. [http://annals.org/article.aspx?articleid=698987 link to original article] [https://pubmed.ncbi.nlm.nih.gov/6206757 PubMed] | + | #Harker WG, Kushlan P, Rosenberg SA. Combination chemotherapy for advanced Hodgkin's disease after failure of MOPP: ABVD and B-CAVe. Ann Intern Med. 1984 Oct;101(4):440-6. [http://annals.org/article.aspx?articleid=698987 link to original article] [https://pubmed.ncbi.nlm.nih.gov/6206757 PubMed] |
− | |||
==BVCPP {{#subobject:cb42cf|Regimen=1}}== | ==BVCPP {{#subobject:cb42cf|Regimen=1}}== | ||
{| class="wikitable" style="float:right; margin-left: 5px;" | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
Line 874: | Line 1,031: | ||
|[[#top|back to top]] | |[[#top|back to top]] | ||
|} | |} | ||
− | |||
BVCPP: '''<u>B</u>'''CNU (Carmustine), '''<u>V</u>'''inblastine, '''<u>C</u>'''yclophosphamide, '''<u>P</u>'''rocarbazine, '''<u>P</u>'''rednisone | BVCPP: '''<u>B</u>'''CNU (Carmustine), '''<u>V</u>'''inblastine, '''<u>C</u>'''yclophosphamide, '''<u>P</u>'''rocarbazine, '''<u>P</u>'''rednisone | ||
− | |||
===Regimen {{#subobject:514e7d|Variant=1}}=== | ===Regimen {{#subobject:514e7d|Variant=1}}=== | ||
− | {| class="wikitable" style="width: 40%; text-align:center;" | + | {| class="wikitable" style="width: 40%; text-align:center;" |
− | !style="width: 25%"|Study | + | ! style="width: 25%" |Study |
− | !style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]] | + | ! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]] |
|- | |- | ||
|[https://onlinelibrary.wiley.com/doi/abs/10.1002/1097-0142%28197811%2942%3A5%3C2101%3A%3AAID-CNCR2820420504%3E3.0.CO%3B2-M Durant et al. 1978] | |[https://onlinelibrary.wiley.com/doi/abs/10.1002/1097-0142%28197811%2942%3A5%3C2101%3A%3AAID-CNCR2820420504%3E3.0.CO%3B2-M Durant et al. 1978] | ||
− | |style="background-color:#91cf61"|Non-randomized | + | | style="background-color:#91cf61" |Non-randomized |
|- | |- | ||
|} | |} | ||
Line 894: | Line 1,049: | ||
====Subsequent treatment==== | ====Subsequent treatment==== | ||
*Patients who achieved CR: No additional therapy versus [[Hodgkin_lymphoma#MOPP|MOPP]] x 6 versus BVCPP x 6 additional cycles | *Patients who achieved CR: No additional therapy versus [[Hodgkin_lymphoma#MOPP|MOPP]] x 6 versus BVCPP x 6 additional cycles | ||
− | |||
===References=== | ===References=== | ||
− | # Durant JR, Gams RA, Velez-Garcia E, Bartolucci A, Wirtschafter D, Dorfman R. BCNU, velban, cyclophosphamide, procarbazine, and prednisone (BVCPP) in advanced Hodgkin's disease. Cancer. 1978 Nov;42(5):2101-10. [https://onlinelibrary.wiley.com/doi/abs/10.1002/1097-0142%28197811%2942%3A5%3C2101%3A%3AAID-CNCR2820420504%3E3.0.CO%3B2-M link to original article] [https://pubmed.ncbi.nlm.nih.gov/719600 PubMed] | + | #Durant JR, Gams RA, Velez-Garcia E, Bartolucci A, Wirtschafter D, Dorfman R. BCNU, velban, cyclophosphamide, procarbazine, and prednisone (BVCPP) in advanced Hodgkin's disease. Cancer. 1978 Nov;42(5):2101-10. [https://onlinelibrary.wiley.com/doi/abs/10.1002/1097-0142%28197811%2942%3A5%3C2101%3A%3AAID-CNCR2820420504%3E3.0.CO%3B2-M link to original article] [https://pubmed.ncbi.nlm.nih.gov/719600 PubMed] |
− | |||
==BVDS {{#subobject:3a24f9|Regimen=1}}== | ==BVDS {{#subobject:3a24f9|Regimen=1}}== | ||
{| class="wikitable" style="float:right; margin-left: 5px;" | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
Line 905: | Line 1,058: | ||
BVDS: '''<u>B</u>'''leomycin, '''<u>V</u>'''inblastine, '''<u>D</u>'''oxorubicin, '''<u>S</u>'''treptozocin | BVDS: '''<u>B</u>'''leomycin, '''<u>V</u>'''inblastine, '''<u>D</u>'''oxorubicin, '''<u>S</u>'''treptozocin | ||
===Regimen {{#subobject:41d09e|Variant=1}}=== | ===Regimen {{#subobject:41d09e|Variant=1}}=== | ||
− | {| class="wikitable" style="width: 40%; text-align:center;" | + | {| class="wikitable" style="width: 40%; text-align:center;" |
− | !style="width: 25%"|Study | + | ! style="width: 25%" |Study |
− | !style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]] | + | ! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]] |
|- | |- | ||
|[https://jamanetwork.com/journals/jama/article-abstract/350618 Vinciguerra et al. 1977] | |[https://jamanetwork.com/journals/jama/article-abstract/350618 Vinciguerra et al. 1977] | ||
Line 919: | Line 1,072: | ||
*[[Streptozocin (Zanosar)]] | *[[Streptozocin (Zanosar)]] | ||
===References=== | ===References=== | ||
− | # Vinciguerra V, Coleman M, Jarowski CI, Degnan TJ, Silver RT. A new combination chemotherapy for resistant Hodgkin disease. JAMA. 1977 Jan 3;237(1):33-5. [https://jamanetwork.com/journals/jama/article-abstract/350618 link to original article] [https://pubmed.ncbi.nlm.nih.gov/62854 PubMed] | + | #Vinciguerra V, Coleman M, Jarowski CI, Degnan TJ, Silver RT. A new combination chemotherapy for resistant Hodgkin disease. JAMA. 1977 Jan 3;237(1):33-5. [https://jamanetwork.com/journals/jama/article-abstract/350618 link to original article] [https://pubmed.ncbi.nlm.nih.gov/62854 PubMed] |
− | |||
==CEP {{#subobject:a1a2cc|Regimen=1}}== | ==CEP {{#subobject:a1a2cc|Regimen=1}}== | ||
{| class="wikitable" style="float:right; margin-left: 5px;" | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
Line 926: | Line 1,078: | ||
|[[#top|back to top]] | |[[#top|back to top]] | ||
|} | |} | ||
− | |||
CEP: '''<u>C</u>'''CNU (Lomustine), '''<u>E</u>'''toposide, '''<u>P</u>'''rednimustine | CEP: '''<u>C</u>'''CNU (Lomustine), '''<u>E</u>'''toposide, '''<u>P</u>'''rednimustine | ||
− | |||
===Regimen {{#subobject:a353e9|Variant=1}}=== | ===Regimen {{#subobject:a353e9|Variant=1}}=== | ||
− | {| class="wikitable" style="width: 40%; text-align:center;" | + | {| class="wikitable" style="width: 40%; text-align:center;" |
− | !style="width: 25%"|Study | + | ! style="width: 25%" |Study |
− | !style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]] | + | ! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]] |
|- | |- | ||
|[https://pubmed.ncbi.nlm.nih.gov/2420012 Santoro et al. 1986] | |[https://pubmed.ncbi.nlm.nih.gov/2420012 Santoro et al. 1986] | ||
− | |style="background-color:#91cf61"|Non-randomized | + | | style="background-color:#91cf61" |Non-randomized |
|- | |- | ||
|} | |} | ||
Line 942: | Line 1,092: | ||
*[[Etoposide (Vepesid)]] | *[[Etoposide (Vepesid)]] | ||
*[[Prednimustine (Stereocyt)]] | *[[Prednimustine (Stereocyt)]] | ||
− | |||
===References=== | ===References=== | ||
− | # Santoro A, Viviani S, Valagussa P, Bonfante V, Bonadonna G. CCNU, etoposide, and prednimustine (CEP) in refractory Hodgkin's disease. Semin Oncol. 1986 Mar;13(1 Suppl 1):23-6. [https://pubmed.ncbi.nlm.nih.gov/2420012 PubMed] | + | #Santoro A, Viviani S, Valagussa P, Bonfante V, Bonadonna G. CCNU, etoposide, and prednimustine (CEP) in refractory Hodgkin's disease. Semin Oncol. 1986 Mar;13(1 Suppl 1):23-6. [https://pubmed.ncbi.nlm.nih.gov/2420012 PubMed] |
− | |||
==CVB {{#subobject:b2b2cc|Regimen=1}}== | ==CVB {{#subobject:b2b2cc|Regimen=1}}== | ||
{| class="wikitable" style="float:right; margin-left: 5px;" | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
Line 953: | Line 1,101: | ||
CVB: '''<u>C</u>'''CNU (Lomustine), '''<u>V</u>'''inblastine, '''<u>B</u>'''leomycin | CVB: '''<u>C</u>'''CNU (Lomustine), '''<u>V</u>'''inblastine, '''<u>B</u>'''leomycin | ||
===Regimen {{#subobject:a464e9|Variant=1}}=== | ===Regimen {{#subobject:a464e9|Variant=1}}=== | ||
− | {| class="wikitable" style="width: 40%; text-align:center;" | + | {| class="wikitable" style="width: 40%; text-align:center;" |
− | !style="width: 25%"|Study | + | ! style="width: 25%" |Study |
− | !style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]] | + | ! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]] |
|- | |- | ||
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(75)92069-3/fulltext Goldman & Dawson 1975] | |[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(75)92069-3/fulltext Goldman & Dawson 1975] | ||
− | |style="background-color:#91cf61"|Non-randomized | + | | style="background-color:#91cf61" |Non-randomized |
|- | |- | ||
|} | |} | ||
Line 965: | Line 1,113: | ||
*[[Vinblastine (Velban)]] | *[[Vinblastine (Velban)]] | ||
*[[Bleomycin (Blenoxane)]] | *[[Bleomycin (Blenoxane)]] | ||
− | |||
===References=== | ===References=== | ||
− | # Goldman JM, Dawson AA. Combination therapy for advanced resistant Hodgkin's disease. Lancet. 1975 Dec 20;2(7947):1224-7. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(75)92069-3/fulltext link to original article] [https://pubmed.ncbi.nlm.nih.gov/53720 PubMed] | + | #Goldman JM, Dawson AA. Combination therapy for advanced resistant Hodgkin's disease. Lancet. 1975 Dec 20;2(7947):1224-7. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(75)92069-3/fulltext link to original article] [https://pubmed.ncbi.nlm.nih.gov/53720 PubMed] |
− | |||
==CVPP {{#subobject:be8f99|Regimen=1}}== | ==CVPP {{#subobject:be8f99|Regimen=1}}== | ||
{| class="wikitable" style="float:right; margin-left: 5px;" | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
Line 976: | Line 1,122: | ||
CVPP: '''<u>C</u>'''CNU (Lomustine), '''<u>V</u>'''inblastine, '''<u>P</u>'''rocarbazine, '''<u>P</u>'''rednisone | CVPP: '''<u>C</u>'''CNU (Lomustine), '''<u>V</u>'''inblastine, '''<u>P</u>'''rocarbazine, '''<u>P</u>'''rednisone | ||
===Regimen {{#subobject:f32d98|Variant=1}}=== | ===Regimen {{#subobject:f32d98|Variant=1}}=== | ||
− | {| class="wikitable sortable" style="width: 100%; text-align:center;" | + | {| class="wikitable sortable" style="width: 100%; text-align:center;" |
− | !style="width: 20%"|Study | + | ! style="width: 20%" |Study |
− | !style="width: 20%"|Years of enrollment | + | ! style="width: 20%" |Years of enrollment |
− | !style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]] | + | ! style="width: 20%" |[[Levels_of_Evidence#Evidence|Evidence]] |
− | !style="width: 20%"|Comparator | + | ! style="width: 20%" |Comparator |
− | !style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | + | ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] |
|- | |- | ||
|[https://doi.org/10.1200/JCO.1986.4.6.838 Vinciguerra et al. 1986] | |[https://doi.org/10.1200/JCO.1986.4.6.838 Vinciguerra et al. 1986] | ||
|1975-1981 | |1975-1981 | ||
− | |style="background-color:#1a9851"|Randomized (C) | + | | style="background-color:#1a9851" |Randomized (C) |
|1. ABOS<br> 2. CVPP/ABOS | |1. ABOS<br> 2. CVPP/ABOS | ||
− | |style="background-color:#ffffbf"|Seems not superior | + | | style="background-color:#ffffbf" |Seems not superior |
|- | |- | ||
|} | |} | ||
Line 995: | Line 1,141: | ||
*[[Procarbazine (Matulane)]] | *[[Procarbazine (Matulane)]] | ||
*[[Prednisone (Sterapred)]] | *[[Prednisone (Sterapred)]] | ||
− | |||
===References=== | ===References=== | ||
− | # Vinciguerra V, Propert KJ, Coleman M, Anderson JR, Stutzman L, Pajak TF, Nissen NI, Frizzera G, Gottlieb A, Holland JF; [[Study_Groups#CALGB|CALGB]]. Alternating cycles of combination chemotherapy for patients with recurrent Hodgkin's disease following radiotherapy: a prospectively randomized study by the Cancer and Leukemia Group B. J Clin Oncol. 1986 Jun;4(6):838-46. [https://doi.org/10.1200/JCO.1986.4.6.838 link to original article] [https://pubmed.ncbi.nlm.nih.gov/2423652 PubMed] | + | #Vinciguerra V, Propert KJ, Coleman M, Anderson JR, Stutzman L, Pajak TF, Nissen NI, Frizzera G, Gottlieb A, Holland JF; [[Study_Groups#CALGB|CALGB]]. Alternating cycles of combination chemotherapy for patients with recurrent Hodgkin's disease following radiotherapy: a prospectively randomized study by the Cancer and Leukemia Group B. J Clin Oncol. 1986 Jun;4(6):838-46. [https://doi.org/10.1200/JCO.1986.4.6.838 link to original article] [https://pubmed.ncbi.nlm.nih.gov/2423652 PubMed] |
− | |||
==SCAB {{#subobject:04355f|Regimen=1}}== | ==SCAB {{#subobject:04355f|Regimen=1}}== | ||
{| class="wikitable" style="float:right; margin-left: 5px;" | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
Line 1,004: | Line 1,148: | ||
|[[#top|back to top]] | |[[#top|back to top]] | ||
|} | |} | ||
− | |||
SCAB: '''<u>S</u>'''treptozocin, '''<u>C</u>'''CNU (Lomustine), '''<u>A</u>'''driamycin (Doxorubicin), '''<u>B</u>'''leomycin | SCAB: '''<u>S</u>'''treptozocin, '''<u>C</u>'''CNU (Lomustine), '''<u>A</u>'''driamycin (Doxorubicin), '''<u>B</u>'''leomycin | ||
− | |||
===Regimen {{#subobject:5c34db|Variant=1}}=== | ===Regimen {{#subobject:5c34db|Variant=1}}=== | ||
− | {| class="wikitable" style="width: 40%; text-align:center;" | + | {| class="wikitable" style="width: 40%; text-align:center;" |
− | !style="width: 25%"|Study | + | ! style="width: 25%" |Study |
− | !style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]] | + | ! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]] |
|- | |- | ||
|[https://doi.org/10.1002/mpo.2950030106 Levi et al. 1977] | |[https://doi.org/10.1002/mpo.2950030106 Levi et al. 1977] | ||
− | |style="background-color:#ffffbe"|Non-randomized, <20 pts | + | | style="background-color:#ffffbe" |Non-randomized, <20 pts |
|- | |- | ||
|} | |} | ||
Line 1,021: | Line 1,163: | ||
*[[Doxorubicin (Adriamycin)]] | *[[Doxorubicin (Adriamycin)]] | ||
*[[Bleomycin (Blenoxane)]] | *[[Bleomycin (Blenoxane)]] | ||
− | |||
===References=== | ===References=== | ||
− | # Levi JA, Wiernik PH, Diggs CH. Combination chemotherapy of advanced previously treated Hodgkin's disease with streptozotocin, CCNU, adriamycin and bleomycin. Med Pediatr Oncol. 1977;3(1):33-40. [https://doi.org/10.1002/mpo.2950030106 link to original article] [https://pubmed.ncbi.nlm.nih.gov/65727 PubMed] | + | #Levi JA, Wiernik PH, Diggs CH. Combination chemotherapy of advanced previously treated Hodgkin's disease with streptozotocin, CCNU, adriamycin and bleomycin. Med Pediatr Oncol. 1977;3(1):33-40. [https://doi.org/10.1002/mpo.2950030106 link to original article] [https://pubmed.ncbi.nlm.nih.gov/65727 PubMed] |
− | |||
=Relapsed or refractory, further lines of therapy= | =Relapsed or refractory, further lines of therapy= | ||
==Carmustine monotherapy {{#subobject:f072cf|Regimen=1}}== | ==Carmustine monotherapy {{#subobject:f072cf|Regimen=1}}== | ||
Line 1,032: | Line 1,172: | ||
|} | |} | ||
===Regimen {{#subobject:d61e28|Variant=1}}=== | ===Regimen {{#subobject:d61e28|Variant=1}}=== | ||
− | {| class="wikitable" style="width: 40%; text-align:center;" | + | {| class="wikitable" style="width: 40%; text-align:center;" |
− | !style="width: 25%"|Study | + | ! style="width: 25%" |Study |
− | !style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]] | + | ! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]] |
|- | |- | ||
|[https://www.nejm.org/doi/full/10.1056/NEJM197108262850902 Young et al. 1971] | |[https://www.nejm.org/doi/full/10.1056/NEJM197108262850902 Young et al. 1971] | ||
Line 1,042: | Line 1,182: | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
*[[Carmustine (BCNU)]] | *[[Carmustine (BCNU)]] | ||
− | |||
===References=== | ===References=== | ||
− | # Young RC, DeVita VT Jr, Serpick AA, Canellos GP. Treatment of advanced Hodgkin's disease with (1,3 bis (2-chloroethyl)-1-nitrosourea) BCNU. N Engl J Med. 1971 Aug 26;285(9):475-9. [https://www.nejm.org/doi/full/10.1056/NEJM197108262850902 link to original article] [https://pubmed.ncbi.nlm.nih.gov/5558887 PubMed] | + | #Young RC, DeVita VT Jr, Serpick AA, Canellos GP. Treatment of advanced Hodgkin's disease with (1,3 bis (2-chloroethyl)-1-nitrosourea) BCNU. N Engl J Med. 1971 Aug 26;285(9):475-9. [https://www.nejm.org/doi/full/10.1056/NEJM197108262850902 link to original article] [https://pubmed.ncbi.nlm.nih.gov/5558887 PubMed] |
− | |||
==Doxorubicin & Lomustine {{#subobject:7e7049|Regimen=1}}== | ==Doxorubicin & Lomustine {{#subobject:7e7049|Regimen=1}}== | ||
{| class="wikitable" style="float:right; margin-left: 5px;" | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
Line 1,052: | Line 1,190: | ||
|} | |} | ||
===Regimen {{#subobject:e9f038|Variant=1}}=== | ===Regimen {{#subobject:e9f038|Variant=1}}=== | ||
− | {| class="wikitable" style="width: 40%; text-align:center;" | + | {| class="wikitable" style="width: 40%; text-align:center;" |
− | !style="width: 25%"|Study | + | ! style="width: 25%" |Study |
− | !style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]] | + | ! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]] |
|- | |- | ||
|[https://jamanetwork.com/journals/jama/article-abstract/355977 Williams & Einhorn 1977] | |[https://jamanetwork.com/journals/jama/article-abstract/355977 Williams & Einhorn 1977] | ||
Line 1,064: | Line 1,202: | ||
*[[Lomustine (CCNU)]] | *[[Lomustine (CCNU)]] | ||
===References=== | ===References=== | ||
− | # Williams SD, Einhorn LH. Combination chemotherapy with doxorubicin and lomustine: treatment of refractory Hodgkin's disease. JAMA. 1977 Oct 10;238(15):1659-61. [https://jamanetwork.com/journals/jama/article-abstract/355977 link to original article] [https://pubmed.ncbi.nlm.nih.gov/578254 PubMed] | + | #Williams SD, Einhorn LH. Combination chemotherapy with doxorubicin and lomustine: treatment of refractory Hodgkin's disease. JAMA. 1977 Oct 10;238(15):1659-61. [https://jamanetwork.com/journals/jama/article-abstract/355977 link to original article] [https://pubmed.ncbi.nlm.nih.gov/578254 PubMed] |
− | |||
==Sirolimus & Vorinostat {{#subobject:273a59|Regimen=1}}== | ==Sirolimus & Vorinostat {{#subobject:273a59|Regimen=1}}== | ||
{| class="wikitable" style="float:right; margin-left: 5px;" | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
Line 1,071: | Line 1,208: | ||
|[[#top|back to top]] | |[[#top|back to top]] | ||
|} | |} | ||
− | |||
===Regimen {{#subobject:91d698|Variant=1}}=== | ===Regimen {{#subobject:91d698|Variant=1}}=== | ||
− | {| class="wikitable" style="width: 40%; text-align:center;" | + | {| class="wikitable" style="width: 40%; text-align:center;" |
− | !style="width: 25%"|Study | + | ! style="width: 25%" |Study |
− | !style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]] | + | ! style="width: 25%" |[[Levels_of_Evidence#Evidence|Evidence]] |
|- | |- | ||
|[https://doi.org/10.1158/1078-0432.ccr-20-1215 Janku et al. 2020 (MDACC 2009-0729)] | |[https://doi.org/10.1158/1078-0432.ccr-20-1215 Janku et al. 2020 (MDACC 2009-0729)] | ||
Line 1,081: | Line 1,217: | ||
|- | |- | ||
|} | |} | ||
− | |||
''This is a very heavily pre-treated cohort, median of 6 prior therapies; doses here are one level below MTD and are proposed as the ongoing doses to be studied.'' | ''This is a very heavily pre-treated cohort, median of 6 prior therapies; doses here are one level below MTD and are proposed as the ongoing doses to be studied.'' | ||
====Targeted therapy==== | ====Targeted therapy==== | ||
− | *[[Sirolimus (Rapamune)]] 4 mg PO once per day | + | *[[Sirolimus (Rapamune)]] 4 mg PO once per day |
*[[Vorinostat (Zolinza)]] as follows: | *[[Vorinostat (Zolinza)]] as follows: | ||
− | **Cycle 1: 300 mg PO once per day on days 7 to 28 | + | **Cycle 1: 300 mg PO once per day on days 7 to 28 |
**Subsequent cycles: 300 mg PO once per day on days 1 to 28 | **Subsequent cycles: 300 mg PO once per day on days 1 to 28 | ||
− | |||
'''28-day cycles''' | '''28-day cycles''' | ||
− | |||
===References=== | ===References=== | ||
− | |||
− | |||
+ | #'''MDACC 2009-0729:''' Janku F, Park H, Call SG, Madwani K, Oki Y, Subbiah V, Hong DS, Naing A, Velez-Bravo VM, Barnes TG, Hagemeister FB, Falchook GS, Karp DD, Wheler JJ, Piha-Paul SA, Garrido-Laguna I, Shpall EJ, Fayad LE, Neelapu SS, Meric-Bernstam F, Kurzrock R, Fanale MA. Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma. Clin Cancer Res. 2020 Nov 1;26(21):5579-5587. Epub 2020 Oct 14. [https://doi.org/10.1158/1078-0432.ccr-20-1215 link to original article] [https://pubmed.ncbi.nlm.nih.gov/33055173/ PubMed] NCT01087554 | ||
[[Category:Hodgkin lymphoma regimens]] | [[Category:Hodgkin lymphoma regimens]] | ||
[[Category:Historical regimens]] | [[Category:Historical regimens]] | ||
[[Category:Disease-specific pages]] | [[Category:Disease-specific pages]] | ||
[[Category:Aggressive lymphomas]] | [[Category:Aggressive lymphomas]] |
Revision as of 05:55, 4 February 2022
The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. As a general rule, this includes the inferior arm(s) of a randomized study, unless said regimens continue to be recommended by trustworthy sources such as the NCCN Guidelines. Is there a regimen missing from this list? See the main Hodgkin lymphoma page for current regimens.
30 regimens on this page
37 variants on this page
|
Untreated
ABVDm
back to top |
ABVDm: Adriamycin (Doxorubicin), Bleomycin, Vinblastine, Dacarbazine, methylprednisolone
Regimen
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Le Maignan et al. 2003 (H90-NM) | 1990-1996 | Phase 3 (C) | EBVMm | Seems not superior |
Chemotherapy
- Doxorubicin (Adriamycin)
- Bleomycin (Blenoxane)
- Vinblastine (Velban)
- Dacarbazine (DTIC)
- Methylprednisolone (Solumedrol)
References
- H90-NM: Le Maignan C, Desablens B, Delwail V, Dib M, Berthou C, Vigier M, Ghandour C, Atmani S, Casassus P, Maisonneuve H, Le Mevel A, Traulle C, Bernard M, Briere J, Colonna P, Andrieu JM. Three cycles of adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD) or epirubicin, bleomycin, vinblastine, and methotrexate (EBVM) plus extended field radiation therapy in early and intermediate Hodgkin disease: 10-year results of a randomized trial. Blood. 2004 Jan 1;103(1):58-66. Epub 2003 Aug 7. link to original article PubMed
BCVPP
back to top |
BCVPP: BCNU (Carmustine), Cyclophosphamide, Vincristine, Procarbazine, Prednisone
Regimen
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Durant et al. 1978 | 1971-1975 | Non-randomized portion of RCT | ||
Bakemeier et al. 1984 | 1972-1976 | Phase III (E-esc) | MOPP | Seems not superior1 |
1For patients achieving CR, this regimen seemed to have comparatively superior survival.
Chemotherapy
- Carmustine (BCNU)
- Cyclophosphamide (Cytoxan)
- Vincristine (Oncovin)
- Procarbazine (Matulane)
- Prednisone (Sterapred)
References
- Durant JR, Gams RA, Velez-Garcia E, Bartolucci A, Wirtschafter D, Dorfman R. BCNU, velban, cyclophosphamide, procarbazine, and prednisone (BVCPP) in advanced Hodgkin's disease. Cancer. 1978 Nov;42(5):2101-10. link to original article PubMed
- Bakemeier RF, Anderson JR, Costello W, Rosner G, Horton J, Glick JH, Hines JD, Berard CW, DeVita VT Jr; ECOG. BCVPP chemotherapy for advanced Hodgkin's disease: evidence for greater duration of complete remission, greater survival, and less toxicity than with a MOPP regimen: results of the Eastern Cooperative Oncology Group study. Ann Intern Med. 1984 Oct;101(4):447-56. link to original article PubMed
ChlVPP/PABIOE
back to top |
ChlVPP/PABIOE: Chlorambucil, Vinblastine, Procarbazine, Prednisone alternating with Prednisolone, Adriamycin (Doxorubicin), Bleomycin, Oncovin (Vincristine), Etoposide
Protocol
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Hancock et al. 2001 | 1992-1996 | Randomized (C) | PABIOE | Superior OS |
Chemotherapy, ChlVPP portion
Chemotherapy, PABIOE portion
- Prednisolone (Millipred)
- Doxorubicin (Adriamycin)
- Bleomycin (Blenoxane)
- Vincristine (Oncovin)
- Etoposide (Vepesid)
References
- Hancock BW, Gregory WM, Cullen MH, Hudson GV, Burton A, Selby P, Maclennan KA, Jack A, Bessell EM, Smith P, Linch DC; British National Lymphoma Investigation; Central Lymphoma Group. ChlVPP alternating with PABlOE is superior to PABlOE alone in the initial treatment of advanced Hodgkin's disease: results of a British National Lymphoma Investigation/Central Lymphoma Group randomized controlled trial. Br J Cancer. 2001 May 18;84(10):1293-300. link to orginal article link to PMC article PubMed
- UKLG LY09: Johnson PW, Radford JA, Cullen MH, Sydes MR, Walewski J, Jack AS, MacLennan KA, Stenning SP, Clawson S, Smith P, Ryder D, Hancock BW; United Kingdom Lymphoma Group. Comparison of ABVD and alternating or hybrid multidrug regimens for the treatment of advanced Hodgkin's lymphoma: results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519). J Clin Oncol. 2005 Dec 20;23(36):9208-18. Epub 2005 Nov 28. link to original article contains verified protocol PubMed ISRCTN97144519
- Subgroup analysis: Johnson PW, Sydes MR, Hancock BW, Cullen M, Radford JA, Stenning SP. Consolidation radiotherapy in patients with advanced Hodgkin's lymphoma: survival data from the UKLG LY09 randomized controlled trial (ISRCTN97144519). J Clin Oncol. 2010 Jul 10;28(20):3352-9. Epub 2010 May 24. link to original article PubMed
COMP
back to top |
COMP: Cyclophosphamide, Oncovin (Vincristine), Methotrexate, Prednisone
Regimen
Study | Evidence |
---|---|
Moxley et al. 1967 | Pilot |
Chemotherapy
References
- Moxley JH 3rd, De Vita VT, Brace K, Frei E 3rd. Intensive combination chemotherapy and X-irradiation in Hodgkin's disease. Cancer Res. 1967 Jul;27(7):1258-63. link to original article PubMed
COPP (CCNU)
back to top |
COPP: CCNU (Lomustine), Oncovin (Vincristine), Procarbazine, Prednisone
Regimen
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Cooper et al. 1980 | 1972-1975 | Phase III (E-switch-ic) | 1. CVPP | Seems not superior |
2. MOPP | Seems not superior | |||
3. MVPP | Seems not superior |
Chemotherapy
References
- Cooper MR, Pajak TF, Nissen NI, Stutzman L, Brunner K, Cuttner J, Falkson G, Grunwald H, Bank A, Leone L, Seligman BR, Silver RT, Weiss RB, Haurani F, Blom J, Spurr CL, Glidewell OJ, Gottlieb AJ, Holland JF. A new effective four-drug combination of CCNU (1-[2-chloroethyl]-3-cyclohexyl-1-nitrosourea) (NSC-79038), vinblastine, prednisone, and procarbazine for the treatment of advanced Hodgkin's disease. Cancer. 1980 Aug 15;46(4):654-62. link to original article PubMed
COPP/ABVD
back to top |
COPP/ABVD: Cyclophosphamide, Oncovin (Vincristine), Procarbazine, Prednisone alternating with Adriamycin (Doxorubicin), Bleomycin, Vinblastine, Dacarbazine
C-MOPP/ABVD: CyclophosphaMide, Oncovin (Vincristine), Procarbazine, Prednisone alternating with Adriamycin (Doxorubicin), Bleomycin, Vinblastine, Dacarbazine
Protocol variant #1, 4 cycles
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Sieber et al. 2002 (GHSG HD5) | 1988-1993 | Phase III (C) | COPP/ABV/IMEP | Seems not superior |
Sieber et al. 2004 (GHSG HD6) | 1988-1993 | Phase III (C) | COPP/ABV/IMEP | Seems not superior |
Engert et al. 2003 (GHSG HD8) | 1993-1998 | Non-randomized portion of RCT |
Chemotherapy, COPP portion
28-day cycle for 2 total cycles of COPP, alternating with 2 total cycles of ABVD
Chemotherapy, ABVD portion
28-day cycle for 2 total cycles of ABVD, alternating with 2 total cycles of COPP
Subsequent treatment
Protocol variant #2, 6 cycles
Study | Evidence |
---|---|
Diehl et al. 1995 (GHSG HD3) | Non-randomized portion of RCT |
Chemotherapy, COPP portion
28-day cycle for 3 total cycles of COPP, alternating with 3 total cycles of ABVD
Chemotherapy, ABVD portion
28-day cycle for 3 total cycles of ABVD, alternating with 3 total cycles of COPP
Subsequent treatment
- COPP/ABVD x 1 (8 cycles total) versus IFRT
Protocol variant #3, 10 cycles
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Takenaka et al. 2000 (JCOG 8905) | 1989-1993 | Phase II | ||
Diehl et al. 1998 (GHSG HD9) | 1993-1998 | Phase III (C) | 1. BEACOPP 2. eBEACOPP |
Seems to have inferior OS |
Ballova et al. 2005 (GHSG HD9elderly) | 1993-1998 | Phase III (C) | BEACOPP | Seems not superior |
Chemotherapy, COPP portion
- Cyclophosphamide (Cytoxan) 500 mg/m2 IV once per day on days 1 & 8
- Vincristine (Oncovin) 1.4 mg/m2 (maximum dose of 2 mg) IV once per day on days 1 & 8
- Procarbazine (Matulane) 100 mg/m2 (maximum dose of 150 mg) PO once per day on days 1 to 14
- Prednisone (Sterapred) 40 mg/m2 PO once per day on days 1 to 3, 8 to 10
28-day cycle for 5 total cycles of COPP, alternating with 5 total cycles of ABVD
Chemotherapy, ABVD portion
- Doxorubicin (Adriamycin) 25 mg/m2 IV once per day on days 1 & 15
- Bleomycin (Blenoxane) 9 mg/m2 (maximum of 15 mg per dose) IV once per day on days 1 & 15
- Vinblastine (Velban) 6 mg/m2 (maximum of 10 mg per dose) IV once per day on days 1 & 15
- Dacarbazine (DTIC) 250 mg/m2 IV once per day on days 1 & 15
28-day cycle for 5 total cycles of ABVD, alternating with 5 total cycles of COPP
Subsequent treatment
- Some studies: IFRT x 30 Gy after completion of chemotherapy was given to patients with bulky (at least 10 cm maximum diameter) disease
Dose modifications
- Treatment was postponed for at least 1 week or until recovery if:
- Pretreatment ANC was less than 1500/uL
- Platelet count was less than 100 x 109/L
- AST/S-GOT was greater than 100 IU/L
- Total bilirubin was greater than 2
- Vincristine and vinblastine were temporarily discontinued if patients had grade 2 or greater neurotoxicity (e.g. motor weakness, paresthesia, constipation)
- Doxorubicin was discontinued if cardiac LV ejection fraction was less than 50%
- Bleomycin was stopped if the PaO2 was less than 70 mmHg or if it decreased more than 10 mmHg from the previous measurement
- Note: Dacarbazine 250 mg/m2 was used at this dose reduction based on experiences in a pilot study in which there was severe emesis with 375 mg/m2.
References
- GHSG HD3: Diehl V, Loeffler M, Pfreundschuh M, Ruehl U, Hasenclever D, Nisters-Backes H, Sieber M, Smith K, Tesch H, Geilen W, Adler M, Bartels H, Brandenburg U, Diezler P, Doelken G, Enzian J, Fuchs R, Gassmann W, Gerhartz H, Hagenaukamp U, Hecht T, Hiller E, Hinkelbein H, Lathan B, Kirchner H, Kuehn G, Kuerten H, Loos U, Makoski B, Oertel W, Petsch S, Pfab R, Pflueger H, Planker M, Rohioff R, Sack H, Samandari S, Sauer R, Schalk K, Schmitz G, Schoppe W, Schwieder G, Szepesi S, Teichmann J, Wilhelmy W, Worst P, Fischer R, Georgii A, Huebner E, Schwarze EW; German Hodgkin's Study Group. Further chemotherapy versus low-dose involved-field radiotherapy as consolidation of complete remission after six cycles of alternating chemotherapy in patients with advance Hodgkin's disease. Ann Oncol. 1995 Nov;6(9):901-10. link to original article PubMed
- GHSG HD9: Diehl V, Franklin J, Hasenclever D, Tesch H, Pfreundschuh M, Lathan B, Paulus U, Sieber M, Rueffer JU, Sextro M, Engert A, Wolf J, Hermann R, Holmer L, Stappert-Jahn U, Winnerlein-Trump E, Wulf G, Krause S, Glunz A, von Kalle K, Bischoff H, Haedicke C, Duehmke E, Georgii A, Loeffler M. BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol. 1998 Dec;16(12):3810-21. link to original articlecontains verified protocol PubMed
- Update: Diehl V, Franklin J, Pfreundschuh M, Lathan B, Paulus U, Hasenclever D, Tesch H, Herrmann R, Dörken B, Müller-Hermelink HK, Dühmke E, Loeffler M; German Hodgkin's Lymphoma Study Group. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med. 2003 Jun 12;348(24):2386-95. link to original articlecontains protocol PubMed
- Update: Engert A, Diehl V, Franklin J, Lohri A, Dörken B, Ludwig WD, Koch P, Hänel M, Pfreundschuh M, Wilhelm M, Trümper L, Aulitzky WE, Bentz M, Rummel M, Sezer O, Müller-Hermelink HK, Hasenclever D, Löffler M. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol. 2009 Sep 20;27(27):4548-54. link to original article PubMed
- Update: von Tresckow B, Kreissl S, Dipl-Math HG, Bröckelmann PJ, Pabst T, Fridrik M, Rummel M, Jung W, Thiemer J, Sasse S, Bürkle C, Baues C, Diehl V, Engert A, Borchmann P; German Hodgkin Study Group. Intensive treatment strategies in advanced-stage Hodgkin's lymphoma (HD9 and HD12): analysis of long-term survival in two randomised trials. Lancet Haematol. 2018 Oct 01;5(10):e462-73. link to original article PubMed
- JCOG 8905: Takenaka T, Mikuni C, Miura A, Sasaki T, Suzuki H, Hotta T, Hirano M, Fukuhara S, Sugiyama H, Nasu K, Dohi H, Kozuru M, Tomonaga M, Tajima K, Niimi M, Fukuda H, Mukai K, Shimoyama M; Lymphoma Study Group of the Japan Clinical Oncology Group. Alternating combination chemotherapy C-MOPP (cyclophosphamide, vincristine, procarbazine, prednisone) and ABVd (adriamycin, bleomycin, vinblastine, dacarbazine) in clinical stage II-IV Hodgkin's disease: a multicenter phase II study (JCOG 8905). Jpn J Clin Oncol. 2000 Mar;30(3):146-52. link to original article contains protocol PubMed
- GHSG HD5: Sieber M, Tesch H, Pfistner B, Rueffer U, Lathan B, Brosteanu O, Paulus U, Koch T, Pfreundschuh M, Loeffler M, Engert A, Josting A, Wolf J, Hasenclever D, Franklin J, Duehmke E, Georgii A, Schalk KP, Kirchner H, Doelken G, Munker R, Koch P, Herrmann R, Greil R, Anselmo AP, Diehl V. Rapidly alternating COPP/ABV/IMEP is not superior to conventional alternating COPP/ABVD in combination with extended-field radiotherapy in intermediate-stage Hodgkin's lymphoma: final results of the German Hodgkin's Lymphoma Study Group Trial HD5. J Clin Oncol. 2002 Jan 15;20(2):476-84. link to original article PubMed
- GHSG HD8: Engert A, Schiller P, Josting A, Herrmann R, Koch P, Sieber M, Boissevain F, De Wit M, Mezger J, Duhmke E, Willich N, Muller RP, Schmidt BF, Renner H, Muller-Hermelink HK, Pfistner B, Wolf J, Hasenclever D, Loffler M, Diehl V; German Hodgkin's Lymphoma Study Group. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol. 2003 Oct 1;21(19):3601-8. Epub 2003 Aug 11. link to original article contains protocol PubMed
- Update: Sasse S, Klimm B, Görgen H, Fuchs M, Heyden-Honerkamp A, Lohri A, Koch O, Wilhelm M, Trenn G, Finke J, Müller RP, Diehl V, Eich HT, Borchmann P, Engert A; German Hodgkin Study Group (GHSG). Comparing long-term toxicity and efficacy of combined modality treatment including extended- or involved-field radiotherapy in early-stage Hodgkin's lymphoma. Ann Oncol. 2012 Nov;23(11):2953-9. Epub 2012 Jul 5. link to original article PubMed
- Update: Sasse S, Bröckelmann PJ, Goergen H, Plütschow A, Müller H, Kreissl S, Buerkle C, Borchmann S, Fuchs M, Borchmann P, Diehl V, Engert A. Long-term follow-up of contemporary treatment in early-stage Hodgkin lymphoma: updated analyses of the German Hodgkin Study Group HD7, HD8, HD10, and HD11 trials. J Clin Oncol. 2017 Jun 20;35(18):1999-2007. Epub 2017 Apr 18. link to original article PubMed
- GHSG HD6: Sieber M, Tesch H, Pfistner B, Rueffer U, Paulus U, Munker R, Hermann R, Doelken G, Koch P, Oertel J, Roller S, Worst P, Bischof H, Glunz A, Greil R, von Kalle K, Schalk KP, Hasenclever D, Brosteanu O, Duehmke E, Georgii A, Engert A, Loeffler M, Diehl V, Mueller RP, Willich N, Fischer R, Hansmann ML, Stein H, Schober T, Koch B; German Hodgkin's Lymphoma Study Group. Treatment of advanced Hodgkin's disease with COPP/ABV/IMEP versus COPP/ABVD and consolidating radiotherapy: final results of the German Hodgkin's Lymphoma Study Group HD6 trial. Ann Oncol. 2004 Feb;15(2):276-82. link to original article PubMed
- GHSG HD9elderly: Ballova V, Rüffer JU, Haverkamp H, Pfistner B, Müller-Hermelink HK, Dühmke E, Worst P, Wilhelmy M, Naumann R, Hentrich M, Eich HT, Josting A, Löffler M, Diehl V, Engert A. A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin's disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly). Ann Oncol. 2005 Jan;16(1):124-31. link to original articlecontains protocol PubMed
CVPP
back to top |
CVPP: CCNU (Lomustine), Vinblastine, Procarbazine, Prednisone
Regimen
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Cooper et al. 1980 | 1972-1975 | Phase III (E-switch-ic) | 1. COPP | Seems not superior |
2. MOPP | Seems to have superior CR rate | |||
3. MVPP | Seems not superior | |||
Pavlovsky et al. 1988 | 1977-1986 | Randomized (E-de-esc) | CVPP & RT | Inferior FFS1 |
Pavlovsky et al. 1997 | 1986-NR | Randomized (C) | AOPE | Seems to have superior CR rate |
Sackmann-Muriel et al. 1997 | 1987-1994 | Randomized (C) | AOPE | Seems to have superior EFS |
1No advantage was seen for either arm in the favorable prognosis group, whereas this arm had inferior DFS for the unfavorable prognosis group.
Chemotherapy
References
- Cooper MR, Pajak TF, Nissen NI, Stutzman L, Brunner K, Cuttner J, Falkson G, Grunwald H, Bank A, Leone L, Seligman BR, Silver RT, Weiss RB, Haurani F, Blom J, Spurr CL, Glidewell OJ, Gottlieb AJ, Holland JF. A new effective four-drug combination of CCNU (1-[2-chloroethyl]-3-cyclohexyl-1-nitrosourea) (NSC-79038), vinblastine, prednisone, and procarbazine for the treatment of advanced Hodgkin's disease. Cancer. 1980 Aug 15;46(4):654-62. link to original article PubMed
- Pavlovsky S, Maschio M, Santarelli MT, Sackmann Muriel F, Corrado C, Garcia I, Schwartz L, Montero C, Lobo Sanahuja F, Magnasco O, Raha R, Cavagnaro F. Randomized trial of chemotherapy versus chemotherapy plus radiotherapy for stage I-II Hodgkin's disease. J Natl Cancer Inst. 1988 Nov 16;80(18):1466-73. link to original article PubMed
- Update: Pavlovsky S, Santarelli MT, Sackmann Muriel F, Fernández I, Garcia I, Schwartz L, Montero C, Sanahuja FL, Magnasco H, Costa A, Corrado C, Raha R, Bezares R. Randomized trial of chemotherapy versus chemotherapy plus radiotherapy for stage III-IV A & B Hodgkin's disease. Ann Oncol. 1992 Jul;3(7):533-7. link to original article PubMed
- Pavlovsky S, Schvartzman E, Lastiri F, Magnasco H, Corrado C, Raslawski E, Cancela ME, Ardaiz MC, Cerutti I, Rosso A, Bruno S, Aranguren PN, Salvarezza A, Donato H, Dibar E, Zirone S; GATLA. Randomized trial of CVPP for three versus six cycles in favorable-prognosis and CVPP versus AOPE plus radiotherapy in intermediate-prognosis untreated Hodgkin's disease. J Clin Oncol. 1997 Jul;15(7):2652-8. link to original article PubMed
- Sackmann-Muriel F, Zubizarreta P, Gallo G, Scopinaro M, Alderete D, Alfaro E, Casak S, Chantada G, Felice MS, Quinteros R. Hodgkin disease in children: results of a prospective randomized trial in a single institution in Argentina. Med Pediatr Oncol. 1997 Dec;29(6):544-52. link to original article PubMed
Doxorubicin & Vinblastine
back to top |
Regimen
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Press et al. 2001 (SWOG S9133) | NR-2000 | Phase III (E-esc) | STLI | Superior PFS |
Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.
Chemotherapy
- Doxorubicin (Adriamycin) 25 mg/m2 IV once per day on days 1 & 15
- Vinblastine (Velban) 6 mg/m2 IV once per day on days 1 & 15
28-day cycle for 3 cycles
Subsequent treatment
- STLI
References
- SWOG S9133: Press OW, LeBlanc M, Lichter AS, Grogan TM, Unger JM, Wasserman TH, Gaynor ER, Peterson BA, Miller TP, Fisher RI. Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin's disease. J Clin Oncol. 2001 Nov 15;19(22):4238-44. link to original article contains verified protocol PubMed NCT00002495
LOPP
back to top |
LOPP: Leukeran (Chlorambucil), Oncovin (Vincristine), Procarbazine, Prednisone
Regimen
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Hancock 1986 | 1979-NR | Randomized (E-switch-ic) | MOPP | Seems not superior |
Hancock et al. 1992 | 1983-1989 | Randomized (C) | LOPP/EVAP | Seems to have inferior OS |
Chemotherapy
References
- Hancock BW; British National Lymphoma Investigation. Randomised study of MOPP (mustine, Oncovin, procarbazine, prednisone) against LOPP (Leukeran substituted for mustine) in advanced Hodgkin's disease. Radiother Oncol. 1986 Nov;7(3):215-21. link to original article PubMed
- Update: Hancock BW, Vaughan Hudson G, Vaughan Hudson B, Haybittle JL, Bennett MH, MacLennan KA, Jelliffe AM; BNLI. British National Lymphoma Investigation randomised study of MOPP (mustine, Oncovin, procarbazine, prednisolone) against LOPP (Leukeran substituted for mustine) in advanced Hodgkin's disease--long term results. Br J Cancer. 1991 Apr;63(4):579-82. link to original article link to PMC article PubMed
- Hancock BW, Vaughan Hudson G, Vaughan Hudson B, Bennett MH, MacLennan KA, Haybittle JL, Anderson L, Linch DC; BNLI. LOPP alternating with EVAP is superior to LOPP alone in the initial treatment of advanced Hodgkin's disease: results of a British National Lymphoma Investigation trial. J Clin Oncol. 1992 Aug;10(8):1252-8. link to original article PubMed
LOPP/EVAP
back to top |
LOPP/EVAP: Leukeran (Chlorambucil), Oncovin (Vincristine), Procarbazine, Prednisone alternating with Etoposide, Vinblastine, Adriamycin (Doxorubicin), Prednisone
Protocol
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Hancock et al. 1992 | 1983-1989 | Randomized (E-switch-ic) | LOPP | Seems to have superior OS |
Hancock et al. 1994 | 1990-1991 | Randomized (C) | LOPP-EVA | Superior CR rate |
Chemotherapy, LOPP portion
Chemotherapy, EVAP portion
References
- Hancock BW, Vaughan Hudson G, Vaughan Hudson B, Bennett MH, MacLennan KA, Haybittle JL, Anderson L, Linch DC; BNLI. LOPP alternating with EVAP is superior to LOPP alone in the initial treatment of advanced Hodgkin's disease: results of a British National Lymphoma Investigation trial. J Clin Oncol. 1992 Aug;10(8):1252-8. link to original article PubMed
- Hancock BW, Vaughan Hudson G, Vaughan Hudson B, Linch DC, Anderson L, MacLennan KA; BNLI. Hybrid LOPP/EVA is not better than LOPP alternating with EVAP: a prematurely terminated British National Lymphoma Investigation randomized trial. Ann Oncol. 1994;5 Suppl 2:117-20. link to original article PubMed
Mechlorethamine monotherapy
back to top |
Regimen
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Goodman et al. 1946 | NR | Non-randomized | ||
Jacobson et al. 1946 | 1943-1945 | Non-randomized | ||
Wintrobe et al. 1947 | NR | Non-randomized | ||
Meyer & Overmiller 1949 | 1946-1947 | Non-randomized | ||
Jacobs et al. 1968 | 1960-1963 | Randomized (C) | Cyclophosphamide | Seems not superior |
These references are of major historic interest as they are the first systemic chemotherapy trials in humans. Note that some of these early trials used nitrogen mustards other than mechlorethamine but are grouped here for simplicity.
Chemotherapy
References
- Goodman LS, Wintrobe MM, Dameshek W, Goodman MJ, Gilman A, McLennan MT. Nitrogen mustard therapy; use of methyl-bis (beta-chloroethyl) amine hydrochloride and tris (beta-chloroethyl) amine hydrochloride for Hodgkin's disease, lymphosarcoma, leukemia and certain allied and miscellaneous disorders. J Am Med Assoc. 1946 Sep 21;132:126-32. link to original article PubMed
- Jacobson LO, Spurr CL, Guzman-Barron ES, Smith T, Lushbaugh C, Dick GF. Nitrogen mustard therapy; studies on the effect of methyl-bis (beta-chloroethyl) amine hydrochloride on neoplastic diseases and allied disorders of the hemopoietic system. J Am Med Assoc. 1946 Oct 5;132:263-71. link to original article PubMed
- Wintrobe MM, Huguley CM Jr, McLennan MT, Penna de Carvalho Lima L. Nitrogen mustard as a therapeutic agent for Hodgkin's disease, lymphosarcoma and leukemia. Ann Intern Med. 1947 Oct;27(4):529-40. link to original article PubMed
- Meyer AH, Overmiller WC. The use of nitrogen mustard in Hodgkin's disease and lymphosarcoma. Ann Intern Med. 1949 Feb;30(2):381-6. link to original article PubMed
- Jacobs EM, Peters FC, Luce JK, Zippin C, Wood DA. Mechlorethamine HCl and cyclophosphamide in the treatment of Hodgkin's disease and the lymphomas. JAMA. 1968 Feb 5;203(6):392-8. link to original article PubMed
MOPP/ABVD
back to top |
MOPP/ABVD: Mustargen (Mechlorethamine), Oncovin (Vincristine), Procarbazine, Prednisone alternating with Adriamycin (Doxorubicin), Bleomycin, Vinblastine, Dacarbazine
Protocol
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Santoro et al. 1982 | 1974-1980 | Phase 3 (E-switch-ic) | MOPP | Superior PFS |
Somers et al. 1994 | 1981-1986 | Phase 3 (E-switch-ic) | MOPP | Seems to have superior FFS |
Canellos et al. 1992 (CALGB 8251) | 1982-NR | Phase 3 (E-switch-ic) | 1. ABVD | Seems not superior1 |
2. MOPP | Seems to have superior EFS1 | |||
Viviani et al. 1996 | 1982-1990 | Phase 3 (C) | MOPP-ABVD | Seems not superior |
Connor et al. 1997 (NCIC-CTG HD4) | 1984-1989 | Phase 3 (C) | MOPP-ABV | Seems not superior |
Hutchinson et al. 1998 (CCG-521) | 1986-1990 | Phase 3 (C) | ABVD, then RT | Might have inferior EFS |
1Reported efficacy for CALGB 8251 is based on the 2009 update.
Chemotherapy, MOPP portion
Chemotherapy, ABVD portion
References
- Santoro A, Bonadonna G, Bonfante V, Valagussa P. Alternating drug combinations in the treatment of advanced Hodgkin's disease. N Engl J Med. 1982 Apr 1;306(13):770-5. link to original article PubMed
- Update: Bonadonna G, Valagussa P, Santoro A. Alternating non-cross-resistant combination chemotherapy or MOPP in stage IV Hodgkin's disease: a report of 8-year results. Ann Intern Med. 1986 Jun;104(6):739-46. link to original article PubMed
- CALGB 8251: Canellos GP, Anderson JR, Propert KJ, Nissen N, Cooper MR, Henderson ES, Green MR, Gottlieb A, Peterson BA. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med. 1992 Nov 19;327(21):1478-84. link to original article PubMed
- Update: Canellos GP, Niedzwiecki D. Long-term follow-up of Hodgkin's disease trial. N Engl J Med. 2002 May 2;346(18):1417-8. link to original article PubMed
- Update: Canellos GP, Niedzwiecki D, Johnson JL. Long-term follow-up of survival in Hodgkin's lymphoma. N Engl J Med. 2009 Dec 10;361(24):2390-1. link to original article PubMed
- Somers R, Carde P, Henry-Amar M, Tarayre M, Thomas J, Hagenbeek A, Monconduit M, de Pauw BE, Breed WP, Verdonck L, Burgers JMV, Eghbali H, Zittoun R; EORTC. A randomized study in stage IIIB and IV Hodgkin's disease comparing eight courses of MOPP versus an alteration of MOPP with ABVD: a European Organisation for Research and Treatment of Cancer Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curie controlled clinical trial. J Clin Oncol. 1994 Feb;12(2):279-87. link to original article PubMed
- Viviani S, Bonadonna G, Santoro A, Bonfante V, Zanini M, Devizzi L, Soncini F, Valagussa P. Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin's disease: ten-year results. J Clin Oncol. 1996 May;14(5):1421-30. link to original article PubMed
- NCIC-CTG HD4: Connors JM, Klimo P, Adams G, Burns BF, Cooper I, Meyer RM, O'Reilly SE, Pater J, Quirt I, Sadura A, Shustik C, Skillings J, Sutcliffe S, Verma S, Yoshida S, Zee B. Treatment of advanced Hodgkin's disease with chemotherapy--comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: a report from the National Cancer Institute of Canada clinical trials group. J Clin Oncol. 1997 Apr;15(4):1638-45. Erratum in: J Clin Oncol 1997 Jul;15(7):2762. link to original article PubMed
- CCG-521: Hutchinson RJ, Fryer CJ, Davis PC, Nachman J, Krailo MD, O'Brien RT, Collins RD, Whalen T, Reardon D, Trigg ME, Gilchrist GS. MOPP or radiation in addition to ABVD in the treatment of pathologically staged advanced Hodgkin's disease in children: results of the Children's Cancer Group Phase III Trial. J Clin Oncol. 1998 Mar;16(3):897-906. link to original article PubMed
MVPP
back to top |
MVPP: Mechlorethamine, Vinblastine, Procarbazine, Prednisone
Regimen
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Cooper et al. 1980 | 1972-1975 | Phase III (E-switch-ic) | 1. COPP | Seems not superior |
2. CVPP | Seems not superior | |||
3. MOPP | Seems not superior |
Chemotherapy
References
- Cooper MR, Pajak TF, Nissen NI, Stutzman L, Brunner K, Cuttner J, Falkson G, Grunwald H, Bank A, Leone L, Seligman BR, Silver RT, Weiss RB, Haurani F, Blom J, Spurr CL, Glidewell OJ, Gottlieb AJ, Holland JF. A new effective four-drug combination of CCNU (1-[2-chloroethyl]-3-cyclohexyl-1-nitrosourea) (NSC-79038), vinblastine, prednisone, and procarbazine for the treatment of advanced Hodgkin's disease. Cancer. 1980 Aug 15;46(4):654-62. link to original article PubMed
NOVP
back to top |
NOVP: Novantrone (Mitoxantrone), Oncovin (Vincristine), Vinblastine, Prednisone
Regimen
Study | Evidence |
---|---|
Hagemeister et al. 1990 | Phase II |
Chemotherapy
References
- Hagemeister FB, Cabanillas F, Velásquez WS, Meistrich ML, Liang JC, McLaughlin P, Redman JR, Romaguera JE, Rodríguez MA, Swan F Jr, Fuller LM. NOVP: a novel chemotherapeutic regimen with minimal toxicity for treatment of Hodgkin's disease. Semin Oncol. 1990 Dec;17(6 Suppl 10):34-8. link to original article PubMed
SCAB
back to top |
SCAB: Streptozocin, CCNU (Lomustine), Adriamycin (Doxorubicin), Bleomycin
Regimen
Study | Evidence |
---|---|
Diggs et al. 1981 | Non-randomized |
Chemotherapy
References
- Diggs CH, Wiernik PH, Sutherland JC. Treatment of advanced untreated Hodgkin's disease with SCAB--an alternative to MOPP. Cancer. 1981 Jan 15;47(2):224-8. link to original article PubMed
- Update: Wiernik PH, Schiffer CA. Long-term follow-up of advanced Hodgkin's disease patients treated with a combination of streptozotocin, lomustine (CCNU), doxorubicin and bleomycin (SCAB). J Cancer Res Clin Oncol. 1988;114(1):105-7. link to original article PubMed
Vinblastine monotherapy
back to top |
Regimen
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Stutzman et al. 1966 | 1963-1964 | Randomized (E-switch-ic) | Cyclophosphamide | Superior ORR |
Chemotherapy
References
- Stutzman L, Ezdinli EZ, Stutzman MA. Vinblastine sulfate vs cyclophosphamide in the therapy for lymphoma. JAMA. 1966 Jan 17;195(3):173-8. link to original article PubMed
OPPA
back to top |
OPPA: Oncovin (Vincristine), Procarbazine, Prednisone, Adriamycin (Doxorubicin)
Regimen
Study | Years of enrollment | Evidence |
---|---|---|
Mauz-Körholz et al. 2010 (GPOH-HD-2002) | 2002-2005 | Phase II |
This regimen is meant for girls. Patients with early-stage disease only received the OPPA portion, see text for details.
Chemotherapy
- Vincristine (Oncovin) 1.5 mg/m2 IV once per day on days 1, 8, 15
- Procarbazine (Matulane) 100 mg/m2 PO once per day on days 1 to 15
- Prednisone (Sterapred) 60 mg/m2 PO once per day on days 1 to 15
- Doxorubicin (Adriamycin) 40 mg/m2 IV once per day on days 1 & 15
28-day cycle for 2 cycles
Subsequent treatment
References
- GPOH-HD-2002: Mauz-Körholz C, Hasenclever D, Dörffel W, Ruschke K, Pelz T, Voigt A, Stiefel M, Winkler M, Vilser C, Dieckmann K, Karlén J, Bergsträsser E, Fosså A, Mann G, Hummel M, Klapper W, Stein H, Vordermark D, Kluge R, Körholz D. Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin's lymphoma: the GPOH-HD-2002 study. J Clin Oncol. 2010 Aug 10;28(23):3680-6. Epub 2010 Jul 12. link to original article contains verified protocol PubMed NCT00416832
VAMP (Methotrexate)
back to top |
VAMP: Vinblastine, Adriamycin (Doxorubicin), Methrotrexate, Prednisone
Regimen
Study | Evidence |
---|---|
Metzger et al. 2012 (HOD99) | Phase 2 |
To be completed? This is to be distinguished from the VAMP protocols used in AML and multiple myeloma.
Chemotherapy
4 cycles
Subsequent treatment
- Early responders: Observation versus RT
References
- HOD99: Metzger ML, Weinstein HJ, Hudson MM, Billett AL, Larsen EC, Friedmann A, Howard SC, Donaldson SS, Krasin MJ, Kun LE, Marcus KJ, Yock TI, Tarbell N, Billups CA, Wu J, Link MP. Association between radiotherapy vs no radiotherapy based on early response to VAMP chemotherapy and survival among children with favorable-risk Hodgkin lymphoma. JAMA. 2012 Jun 27;307(24):2609-16. link to original article link to PMC article PubMed
ABVE
back to top |
ABVE: Adriamycin (Doxorubicin), Bleomycin, Vincristine, Etoposide
Regimen
Study | Years of enrollment | Evidence |
---|---|---|
Tebbi et al. 2012 (POG P9426) | 1996-2001 | Non-randomized (see note) |
Note: this trial had a randomization to receive or not receive dexrazoxane. Labeled here as non-randomized because this drug does not have antineoplastic properties.
Chemotherapy
- Doxorubicin (Adriamycin) 25 mg/m2 IV once per day on days 1 & 15
- Bleomycin (Blenoxane) 10 units/m2 IV once per day on days 1 & 15
- Vincristine (Oncovin) 1.5 mg/m2 (maximum dose of 2 mg) IV once per day on days 1 & 15
- Etoposide (Vepesid) 100 mg/m2 IV once per day on days 1 to 5
Supportive medications
- Filgrastim (Neupogen) 5 mcg/kg SC once per day on days 6 to 14, then once per day on days 16 until ANC greater than 1000/uL
28-day cycle for 2 cycles
Subsequent treatment
- CR: IFRT consolidation
- Other than CR: ABVE x 2, then IFRT consolidation
References
- POG P9426: Tebbi CK, Mendenhall NP, London WB, Williams JL, Hutchison RE, Fitzgerald TJ, de Alarcón PA, Schwartz C, Chauvenet A. Response-dependent and reduced treatment in lower risk Hodgkin lymphoma in children and adolescents, results of P9426: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2012 Dec 15;59(7):1259-65. Epub 2012 Aug 21. link to original article link to PMC article contains verified protocol PubMed NCT00002827
MOPP
back to top |
MOPP: Mechlorethamine, Oncovin (Vincristine), Procarbazine, Prednisone
Regimen variant #3, uncapped vincristine
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Young et al. 1973a | 1964-NR | Non-randomized (RT) | ||
Kolygin 1976 | 1970-1975 | Non-randomized (RT) |
Chemotherapy
- Mechlorethamine (Mustargen) 6 mg/m2 IV once per day on days 1 & 8
- Vincristine (Oncovin) 1.4 mg/m2 IV once per day on days 1 & 8
- Procarbazine (Matulane) 100 mg/m2 PO once per day on days 1 to 14
- Prednisone (Sterapred) 40 mg/m2 PO once per day on days 1 to 14
28-day cycle for 6 to 8 cycles
References
- Young RC, DeVita VT, Johnson RE. Hodgkin's disease in childhood. Blood. 1973 Aug;42(2):163-74. link to original article PubMed
- Kolygin BA. Combination chemotherapy of Hodgkin's disease in children. Cancer. 1976 Oct;38(4):1494-7. link to original article PubMed
Consolidation after upfront therapy
C-MOPP
back to top |
C-MOPP: CyclophosphaMide, Oncovin (Vincristine), Procarbazine, Prednisone
COPP: Cyclophosphamide, Oncovin (Vincristine), Procarbazine, Prednisone
Regimen variant #1, 2 cycles
Study | Years of enrollment | Evidence |
---|---|---|
Mauz-Körholz et al. 2010 (GPOH-HD-2002) | 2002-2005 | Phase II |
Preceding treatment
- OPPA x 2
Chemotherapy
- Cyclophosphamide (Cytoxan) 500 mg/m2 IV once per day on days 1 & 8
- Vincristine (Oncovin) 1.5 mg/m2 IV once per day on days 1 & 8
- Prednisone (Sterapred) 40 mg/m2 PO once per day on days 1 to 15
- Procarbazine (Matulane) 100 mg/m2 PO once per day on days 1 to 15
28-day cycle for 2 cycles
Regimen variant #2, 4 cycles
Study | Years of enrollment | Evidence |
---|---|---|
Mauz-Körholz et al. 2010 (GPOH-HD-2002) | 2002-2005 | Phase II |
Preceding treatment
- OPPA x 2
Chemotherapy
- Cyclophosphamide (Cytoxan) 500 mg/m2 IV once per day on days 1 & 8
- Vincristine (Oncovin) 1.5 mg/m2 IV once per day on days 1 & 8
- Prednisone (Sterapred) 40 mg/m2 PO once per day on days 1 to 15
- Procarbazine (Matulane) 100 mg/m2 PO once per day on days 1 to 15
28-day cycle for 4 cycles
References
- GPOH-HD-2002: Mauz-Körholz C, Hasenclever D, Dörffel W, Ruschke K, Pelz T, Voigt A, Stiefel M, Winkler M, Vilser C, Dieckmann K, Karlén J, Bergsträsser E, Fosså A, Mann G, Hummel M, Klapper W, Stein H, Vordermark D, Kluge R, Körholz D. Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin's lymphoma: the GPOH-HD-2002 study. J Clin Oncol. 2010 Aug 10;28(23):3680-6. Epub 2010 Jul 12. link to original article contains verified protocol PubMed NCT00416832
COPDAC
back to top |
COPDAC: Cyclophosphamide, Oncovin (Vincristine), Prednisone, DACarbazine
Regimen variant #1, 2 cycles
Study | Years of enrollment | Evidence |
---|---|---|
Mauz-Körholz et al. 2010 (GPOH-HD-2002) | 2002-2005 | Phase II |
Preceding treatment
- OEPA x 2
Chemotherapy
- Cyclophosphamide (Cytoxan) 500 mg/m2 IV once per day on days 1 & 8
- Vincristine (Oncovin) 1.5 mg/m2 IV once per day on days 1 & 8
- Prednisone (Sterapred) 40 mg/m2 PO once per day on days 1 to 15
- Dacarbazine (DTIC) 250 mg/m2 IV once per day on days 1 to 4
28-day cycle for 2 cycles
Regimen variant #2, 4 cycles
Study | Years of enrollment | Evidence |
---|---|---|
Mauz-Körholz et al. 2010 (GPOH-HD-2002) | 2002-2005 | Phase II |
Preceding treatment
- OEPA x 2
Chemotherapy
- Cyclophosphamide (Cytoxan) 500 mg/m2 IV once per day on days 1 & 8
- Vincristine (Oncovin) 1.5 mg/m2 IV once per day on days 1 & 8
- Prednisone (Sterapred) 40 mg/m2 PO once per day on days 1 to 15
- Dacarbazine (DTIC) 250 mg/m2 IV once per day on days 1 to 4
28-day cycle for 4 cycles
References
- GPOH-HD-2002: Mauz-Körholz C, Hasenclever D, Dörffel W, Ruschke K, Pelz T, Voigt A, Stiefel M, Winkler M, Vilser C, Dieckmann K, Karlén J, Bergsträsser E, Fosså A, Mann G, Hummel M, Klapper W, Stein H, Vordermark D, Kluge R, Körholz D. Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin's lymphoma: the GPOH-HD-2002 study. J Clin Oncol. 2010 Aug 10;28(23):3680-6. Epub 2010 Jul 12. link to original article contains verified protocol PubMed NCT00416832
Maintenance after upfront therapy
Bacillus Calmette-Guérin (BCG) monotherapy
back to top |
Regimen
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Sokal et al. 1974 | 1965-1967 | Randomized, <20 pts in this subgroup (E-esc) | Observation | Superior PFS |
Note: this study was open to patients with "malignant lymphoma" but the majority had Hodgkin disease.
Immunotherapy
References
- Sokal JE, Aungst CW, Snyderman M. Delay in progression of malignant lymphoma after BCG vaccination. N Engl J Med. 1974 Dec 5;291(23):1226-30. link to original article PubMed
Relapsed or refractory, salvage therapy
ABDIC
back to top |
ABDIC: Adriamycin (Doxorubicin), Bleomycin, DIC (Dacarbazine), CCNU (Lomustine), Prednisone
Regimen
Study | Evidence |
---|---|
Rodgers et al. 1980 | Phase II |
Chemotherapy
- Doxorubicin (Adriamycin)
- Bleomycin (Blenoxane)
- Dacarbazine (DTIC)
- Lomustine (CCNU)
- Prednisone (Sterapred)
References
- Rodgers RW, Gamble JF, Loh KK, Shullenberger CC. Adriamycin, bleomycin, DIC, CCNU, and prednisone (ABDIC) chemotherapy in MOPP-resistant Hodgkin's disease. Cancer. 1980 Dec 1;46(11):2349-55. link to original article PubMed
- Update: Tannir N, Hagemeister F, Velasquez W, Cabanillas F. Long-term follow-up with ABDIC salvage chemotherapy of MOPP-resistant Hodgkin's disease. J Clin Oncol. 1983 Jul;1(7):432-9. link to original article PubMed
ABVD
back to top |
ABVD: Adriamycin (Doxorubicin), Bleomycin, Vinblastine, Dacarbazine
Regimen
Study | Evidence |
---|---|
Krikorian et al. 1978 | Phase II |
Santoro & Bonadonna 1979 | Non-randomized |
Santoro et al. 1982a | Non-randomized |
Harker et al. 1984 | Non-randomized |
This is for historical interest only; ABVD is no longer used in the salvage setting.
Chemotherapy
References
- Krikorian JG, Portlock CS, Rosenberg SA. Treatment of advanced Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide (ABVD) after failure of MOPP therapy. Cancer. 1978 Jun;41(6):2107-11. link to original article PubMed
- Santoro A, Bonadonna G. Prolonged disease-free survival in MOPP-resistant Hodgkin's disease after treatment with adriamycin, bleomycin, vinblastine and dacarbazine (ABVD). Cancer Chemother Pharmacol. 1979;2(2):101-5. link to original article PubMed
- Santoro A, Bonfante V, Bonadonna G. Salvage chemotherapy with ABVD in MOPP-resistant Hodgkin's disease. Ann Intern Med. 1982 Feb;96(2):139-43. link to original article PubMed
- Harker WG, Kushlan P, Rosenberg SA. Combination chemotherapy for advanced Hodgkin's disease after failure of MOPP: ABVD and B-CAVe. Ann Intern Med. 1984 Oct;101(4):440-6. link to original article PubMed
B-CAVe
back to top |
B-CAVe: Bleomycin, CCNU (Lomustine), Adriamycin (Doxorubicin), Vinblastine
Regimen
Study | Evidence |
---|---|
Porzig et al. 1978 | Non-randomized |
Harker et al. 1984 | Non-randomized |
Chemotherapy
References
- Porzig KJ, Portlock CS, Robertson A, Rosenberg SA. Treatment of advanced Hodgkin's disease with B-CAVE following MOPP failure. Cancer. 1978 May;41(5):1670-5. link to original article PubMed
- Harker WG, Kushlan P, Rosenberg SA. Combination chemotherapy for advanced Hodgkin's disease after failure of MOPP: ABVD and B-CAVe. Ann Intern Med. 1984 Oct;101(4):440-6. link to original article PubMed
BVCPP
back to top |
BVCPP: BCNU (Carmustine), Vinblastine, Cyclophosphamide, Procarbazine, Prednisone
Regimen
Study | Evidence |
---|---|
Durant et al. 1978 | Non-randomized |
Chemotherapy
- Carmustine (BCNU)
- Vinblastine (Velban)
- Cyclophosphamide (Cytoxan)
- Procarbazine (Matulane)
- Prednisone (Sterapred)
Subsequent treatment
- Patients who achieved CR: No additional therapy versus MOPP x 6 versus BVCPP x 6 additional cycles
References
- Durant JR, Gams RA, Velez-Garcia E, Bartolucci A, Wirtschafter D, Dorfman R. BCNU, velban, cyclophosphamide, procarbazine, and prednisone (BVCPP) in advanced Hodgkin's disease. Cancer. 1978 Nov;42(5):2101-10. link to original article PubMed
BVDS
back to top |
BVDS: Bleomycin, Vinblastine, Doxorubicin, Streptozocin
Regimen
Study | Evidence |
---|---|
Vinciguerra et al. 1977 | Non-randomized, <20 pts |
Chemotherapy
References
- Vinciguerra V, Coleman M, Jarowski CI, Degnan TJ, Silver RT. A new combination chemotherapy for resistant Hodgkin disease. JAMA. 1977 Jan 3;237(1):33-5. link to original article PubMed
CEP
back to top |
CEP: CCNU (Lomustine), Etoposide, Prednimustine
Regimen
Study | Evidence |
---|---|
Santoro et al. 1986 | Non-randomized |
Chemotherapy
References
- Santoro A, Viviani S, Valagussa P, Bonfante V, Bonadonna G. CCNU, etoposide, and prednimustine (CEP) in refractory Hodgkin's disease. Semin Oncol. 1986 Mar;13(1 Suppl 1):23-6. PubMed
CVB
back to top |
CVB: CCNU (Lomustine), Vinblastine, Bleomycin
Regimen
Study | Evidence |
---|---|
Goldman & Dawson 1975 | Non-randomized |
Chemotherapy
References
- Goldman JM, Dawson AA. Combination therapy for advanced resistant Hodgkin's disease. Lancet. 1975 Dec 20;2(7947):1224-7. link to original article PubMed
CVPP
back to top |
CVPP: CCNU (Lomustine), Vinblastine, Procarbazine, Prednisone
Regimen
Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Vinciguerra et al. 1986 | 1975-1981 | Randomized (C) | 1. ABOS 2. CVPP/ABOS |
Seems not superior |
Chemotherapy
References
- Vinciguerra V, Propert KJ, Coleman M, Anderson JR, Stutzman L, Pajak TF, Nissen NI, Frizzera G, Gottlieb A, Holland JF; CALGB. Alternating cycles of combination chemotherapy for patients with recurrent Hodgkin's disease following radiotherapy: a prospectively randomized study by the Cancer and Leukemia Group B. J Clin Oncol. 1986 Jun;4(6):838-46. link to original article PubMed
SCAB
back to top |
SCAB: Streptozocin, CCNU (Lomustine), Adriamycin (Doxorubicin), Bleomycin
Regimen
Study | Evidence |
---|---|
Levi et al. 1977 | Non-randomized, <20 pts |
Chemotherapy
References
- Levi JA, Wiernik PH, Diggs CH. Combination chemotherapy of advanced previously treated Hodgkin's disease with streptozotocin, CCNU, adriamycin and bleomycin. Med Pediatr Oncol. 1977;3(1):33-40. link to original article PubMed
Relapsed or refractory, further lines of therapy
Carmustine monotherapy
back to top |
Regimen
Study | Evidence |
---|---|
Young et al. 1971 | Non-randomized |
Chemotherapy
References
- Young RC, DeVita VT Jr, Serpick AA, Canellos GP. Treatment of advanced Hodgkin's disease with (1,3 bis (2-chloroethyl)-1-nitrosourea) BCNU. N Engl J Med. 1971 Aug 26;285(9):475-9. link to original article PubMed
Doxorubicin & Lomustine
back to top |
Regimen
Study | Evidence |
---|---|
Williams & Einhorn 1977 | Non-randomized, <20 pts |
Chemotherapy
References
- Williams SD, Einhorn LH. Combination chemotherapy with doxorubicin and lomustine: treatment of refractory Hodgkin's disease. JAMA. 1977 Oct 10;238(15):1659-61. link to original article PubMed
Sirolimus & Vorinostat
back to top |
Regimen
Study | Evidence |
---|---|
Janku et al. 2020 (MDACC 2009-0729) | Non-randomized |
This is a very heavily pre-treated cohort, median of 6 prior therapies; doses here are one level below MTD and are proposed as the ongoing doses to be studied.
Targeted therapy
- Sirolimus (Rapamune) 4 mg PO once per day
- Vorinostat (Zolinza) as follows:
- Cycle 1: 300 mg PO once per day on days 7 to 28
- Subsequent cycles: 300 mg PO once per day on days 1 to 28
28-day cycles
References
- MDACC 2009-0729: Janku F, Park H, Call SG, Madwani K, Oki Y, Subbiah V, Hong DS, Naing A, Velez-Bravo VM, Barnes TG, Hagemeister FB, Falchook GS, Karp DD, Wheler JJ, Piha-Paul SA, Garrido-Laguna I, Shpall EJ, Fayad LE, Neelapu SS, Meric-Bernstam F, Kurzrock R, Fanale MA. Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma. Clin Cancer Res. 2020 Nov 1;26(21):5579-5587. Epub 2020 Oct 14. link to original article PubMed NCT01087554